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Résumé 
 
Catalyses homogènes et enzymatiques se situent dans un premier rang pour la 
création des catalyseurs efficaces plus souvent utilisés dans l’hydrogénation 
énantioselective (industrie et académique). Nos efforts étaient axés sur la création de 
metalloenzymes artificielles basées sur la technologie biotine-(strept)avidine. 
L’ancrage d’un complexe-aminodiphosphine biotinylé dans la (strept)avidine permet 
de créer un catalyseur « hybride » efficace possédant les avantages de catalyseur 
homogène et enzyme. Introduction d’éspaceur chiral dans le composé biotinylé 
(nouvelle génération de métalloenzymes artificielles) montre quelques résultats 
intéressants.  
Le catalyseur le plus efficace était la combinaison de [Rh(COD)Biot-(R)-Pro-
1]+ ⊂ S112W Sav (95% (S)) pour la réduction de N-α-acetamidoacrylique acide  et N-
α-acetamidocinammique acide. Ainsi la nouvelle génération de métalloenzymes 
artificielles montre la résistance en présence de la quantité importante du solvant 
organique. De plus, il est possible d’immobiliser les métalloenzymes artificielles sur 
le support biotine-sepharose grâce aux 4 sites actifs de la (strept)avidine. Une étude 
cinétique réalisée montre que la présence de la protéine peut accélérer la vitesse de la 
réaction (jusqu’à 3 fois par rapport au catalyseur sans protéine).  Enfin, une étude 
thermodynamique exploitant l’incorporation de composé biotinylé [Ru(bpy)2(Biot-
bpy)]2+ dans la (strept)avidine a été réalisée pour le but de déterminer les constantes 
d’affinité de composé biotinylé dans la protéine (5-7 ordres de magnitude plus faible 
par rapport à la biotine).  

Abstract 
 
The present work describes our efforts in the design of artificial 
metalloenzymes based on biotin-(strept)avidin technology. The metal biotinylated-
precursor ensures the activity of the catalyst, whereas the host protein governs the 
enantioselectivity of artificial metalloenzymes. This study focused on the introduction 
of chiral spacer between metal precursor and biotin anchor (second generation of 
artificial hydrogenases), as well as chemo-genetic strategy for screening. The best 
result of the second-generation artificial hydrogenases is combination of 
[Rh(COD)Biot-(R)-Pro-1]+ ⊂ S112W Sav (95% (S)) for the reduction of N-α-
acetamidoacrylic acid  et N-α-acetamidocinammic acid. The second-generation 
artificial hydrogenases displayed high selectivity in the presence of high 
concentration of organic solvent. In addition, as (strept)avidin possesses 4 binding 
sites, it was demonstrated that it is possible to immobilize one binding site leaving 3 
free sites for the incorporation of the biotinylated precursor. The immobilization was 
achieved using commercially available biotin-sepharose.  
Kinetic study shows an increase of reaction rate (up to three fold) using 
artificial metalloenzymes compared to the free-protein catalyst. Moreover, the 
incorporation of biotinylated coordination compounds [Ru(bpy)2(Biot-bpy)]2+ in 
(strept)avidin displays a significant decrease of binding affinity (5-7 orders of 
magnitude) than biotin. 
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 1 
1. INTRODUCTION 
1.1. General aspects 
Metal ions play an important role in the reactivity and diversity of biochemical 
transformations. The successful synthesis of novel complexes that allow application 
of metal ions could have a great impact in many areas of chemistry and biology, 
including medicinal, organic and material chemistry, as well as biochemistry and cell 
biology 1, 2.  
Obtaining useful catalysts (such as those shown in Table 1) remains a major 
challenge for the multibillion-dollar chemical industries that provide raw materials, 
such as fertilizers. One such useful catalyst, methane monooxygenase, can be used to 
obtain alcohol as fuel through either a bio or chemical processes (Table 1). The added 
value of this reaction makes some to consider it a “holy grail” of biochemical 
transformations. Though the synthetic way to carry out this type of catalysis usually 
needs extreme reaction conditions, equivalent biological transformations use ambient 
pressure and temperature. However, an improved synthetic methane monooxygenase 
remains an attractive pursuit, because the robustness of synthetic substances offers 
many advantages over a purely biological approach. 
Table 1. Comparison of chemical and biological systems 3, 4. 
Reaction Chemical System Biological System 
nitrogen fixation N2(g) + 3 H2(g) → 2 NH3(g) 
(α-Fe catalyst, 400-550°C, 100 atm) 
N2 + 8 H+ + 8 e¯ + 16 MgATP → 2 NH3 + H2 + 16 MgADP + 16 Pi 
(nitrogenase) 
methane 
hydroxylation 
CH4 + H2O → CO + 3 H2 
(Ni catalyst, 700-900°C, 1–25 bar) 
CO + 2 H2 → CH3OH 
(Cu/Zn catalyst, 250-280°C, 70-110 
bar) 
CH4 + O2 + NADH + H+ → CH3OH + H2O + NAD+ 
(methane monooxygenase) 
CO oxidation CO + H2O → CO2 + H2 
(Fe/Cu catalyst, >200°C) 
CO + H2O → CO2 + 2 H+ + 2e¯ 
(CO dehydrogenase) 
CO insertion CH3OH + CO → CH3COOH 
[Rh(I)I2(CO2)]¯, 120°C, 30 atm  
CH3−[M] + CO + HS−CoA → CH3(CO)−S−CoA + H+ + [M]¯[a] 
(acetyl-CoA synthase) 
[a]CH3−[M] is a corrinoid-iron-sulfur protein that acts in the reaction as a methyl group donor; HS-CoA 
is coenzyme. 
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Since this thesis is concerned with catalysis, I will present various aspects of 
enzymatic and homogeneous catalysis: kinetics and thermodynamics of catalysts, as 
well as operational condition and organic solvent tolerance. I will also introduce 
artificial metalloenzymes as a new type of catalyst, which offer an attractive 
alternative to both enzymes and homogeneous catalysis. One such type of artificial 
catalyst, investigated in the context of this thesis, uses the biotin-avidin technology; 
therefore, the biotin-avidin technology will be described first in detail.  
1.2. Biotin-Avidin Technology 
1.2.1. Biotin, Avidin & Streptavidin 
Biotin-avidin, often referred to as molecular velcro, is one of the tightest guest 
⊂ host interactions present in nature 5, 6, with a binding constant of Ka ~ 1015 M-1. To 
the best of our knowledge, only two systems display comparable affinities:  
vancomycin ⊂ D-Ala-D-Ala 7, (Ka ~ 1017 M-1) and the interaction of an acetophenone 
derivative in ACEsterase (Ka ~ 1015 M-1) 8. 
The structure of biotin (vitamin H) is depicted in Scheme 1. 
HN NH
S
O
O
H H
OH
 
Scheme 1. Structure of (+)-biotin (D-biotin) 
 
Avidin is a homo-tetrameric glycosylated protein, positively charged at neutral 
pH, found in egg white and oviducts of many bird species, at a maximum 
concentration of about 0.05% of the total protein weight. Like avidin, streptavidin is a 
 3 
homo-tetrameric protein found in certain gram-negative bacteria, which displays a 
high affinity for biotin. In contrast to avidin, streptavidin is non-glycosylated and 
displays a much lower pI = 6.2 9, 10.  
Comparison of the primary structure of these two proteins shows moderate 
sequence homology, 30% identity and 41% similarity 11. The tertiary structure of a 
monomer of avidin and streptavidin is depicted in Scheme 2, whereas the quaternary 
structure of homotetrameric streptavidin is shown in Scheme 3.  
 
Scheme 2. Schematic structure of monomer of avidin (A) and streptavidin (B). Biotin (shown in stick) 
is located in the binding pocket of (strept)avidin (hereafter refers to either streptavidin or avidin). 
Coordinates obtained from PDB: 1AVD and 1SWE. 
 
The origin of the strong binding biotin-streptavidin relies on both hydrophobic 
and hydrophilic interactions between biotin and several amino-acid residues in the 
biotin-binding site 11-14.  
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Scheme 3. Schematic structure of homo-tetrameric streptavidin (PDB: 1SWE). 
1.2.2. Uses of the biotin-(strept)avidin technology 
Many aspects of biotin ⊂ avidin interactions have been extremely well 
characterized. The most relevant to this thesis are: 
 Green and coworkers, as well as many other groups 5, 6, 9-13 have studied biotin-
avidin interaction in detail, both  thermodynamically and structurally. 
 The valeric chain of biotin can be easily modified and conjugated synthetically to 
a metal cofactor yielding little loss in terms of binding affinity of biotin analog in 
(strept)avidin 15-28. 
 The tetrameric nature avidin allows the attachment of different biotinylated 
compounds for various purposes (probing, labeling, treatment of disease, marker, and 
so forth) 29-34. 
It is noteworthy that the strong interaction between biotin or biotinylated 
compounds and (strept)avidin has found many applications in medical diagnostics, 
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immunoassays, cytochemistry, nanoscience, biomolecule detection 35-41, as well as in 
radiolabeling techniques, enzymatic reactions, and fluorescence for visualization 16-19, 
42, 43. 
1.2.2.1. Determination of stability constants 
The determination of stability constants in biotin (or biotin analogs)-
(strept)avidin systems has emerged as a critical issue recently, especially in the 
growing field of molecular recognition. Among the available techniques to determine 
association constants, fluorescence-based assays are some of the most 
straightforward, rapid and sensitive detection techniques 44-48. This technique could be 
achieved by linking covalently a fluorescent dye to biotin, followed by fluorescence 
detection of the biotinylated molecule through cross-linking with (strept)avidin. 
However, biotinylated organic dyes have been shown to lose their luminescence 
intensity upon binding to avidin due to the resonance energy transfer mechanism 49, 50. 
To overcome this problem, long spacer, such as poly(ethylene) glycol, has been used 
to increase the distance between the biotin-conjugated organic dyes and (strept)avidin.  
The design of Re(I)-, Ir(III)-, and Ru(II)-polypyridine conjugated to the biotin 
moiety was proposed by Lo and coworkers 16-19. The study relied on the determination 
of the formation constants of the complex in avidin using spectroscopic titrations. For 
the titrations of avidin with metal-polypyridine complex, they observed two intense 
absorption bands, first at ca. 288 nm which were assigned to intraligand transition (π-
π*) (bpy and ligand attached to biotin), and absorption bands in the region 423-458 
nm which correspond to metal ligand charge-transfer (MLCT) transition.  
Using a slightly different structure of biotinylated compounds (Scheme 4, 
phenantroline as ligand instead of bipyridine), Sleiman and coworkers 23 determined 
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the binding affinity of (poly)phenantroline complexes within (strept)avidin. To 
determine the stability constants, the HABA assays were performed.  
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Scheme 4. Two class of Ru(II)-phenantroline-biotin complexes (a) and (b) 23 
 
HABA (2-(4’-hydroxyazoybenzene)benzoic acid) is an organic dye that binds 
to (strept)avidin in a similar fashion as native biotin, but with much lower affinity (its 
binding constant is 9 orders magnitude lower than biotin) 5, 6, 12, 21. The interactions of 
HABA with amino acid residues in streptavidin are depicted in Scheme 5, as 
comparison interactions of native biotin are also highlighted 13. 
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Scheme 5. Schematic illustration of biotin (left side) and HABA (right side) binding to streptavidin. 
 
Upon addition of the biotinylated metal complexes (Scheme 4) to the mixture 
of HABA ⊂ (strept)avidin, HABA is displaced quantitatively from the biotin binding 
pocket. This displacement can be followed by UV-vis detection at 500 nm. UV-Vis 
titrations can be performed to compare the strength of the binding constants of 
biotinylated conjugates and native biotin. These measurements revealed that the 
association constant of biotinylated compounds is typically 4-5 orders of magnitude 
weaker than biotin. It is important to note that the equivalence points of competition 
titrations using biotinylated compounds with low binding constants (7-8 magnitudes 
lower than that of biotin) were difficult to observe 16, 19.  
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Our group 21 reported recently the determination of the binding constant for 
Rh-diphosphine biotinylated, [Rh(COD)(Biot-1)]+ complex (as illustrated in Scheme 
6) in (strept)avidin. In these studies, the method of HABA displacement was 
performed and the collected data were treated by the nonlinear least-squares method.  
N
PPh2
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NHHN
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Scheme 6. Strcture of [Rh(COD)(Biot-1)]+ complex 
The estimated stability constants were ca. 7 magnitudes lower compared to 
those of native biotin. HABA assays suggested that the Rh-diphosphine complex 
binds to (strept)avidin more tightly than HABA.  
1.2.2.2. Cooperativity 
The term cooperativity refers to the influence of a ligand to the binding 
strength of the subsequent ligands 51, 52. A monovalent ligand (ball in Scheme 7) can 
occupy each binding pocket of a bivalent receptor via reversible reaction 
characterized by the microscopic intermolecular constant (k). It is important to 
distinguish between macroscopic (K) and microscopic constants. Microscopic 
constant characterizes the nature of individual binding events 53.  
k22
k12
k21k11
 
Scheme 7. Microscopic constants of binding a monovalent-donor ligand into a bivalent-receptor. 
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To simplify this system, it is assumed that the 2 binding sites are identical (kI = 
microscopic constant when ligand occupies one binding site of bivalent receptor, kII = 
microscopic constant when both binding sites of receptor are occupied) then k11 = k21 
= kI and k12 = k22 = kII. Thus for the independent active sites, kI = kII = Q.  
Assessment of cooperativity is performed by comparing the ratio of binding 
constants with a theoretical/statistical one, obtained from equation 2. Non-
cooperativity (additive) is found when the equality occurs. In the case that the binding 
of the ligand favors the binding of the subsequent ligand, then the system is 
considered positively cooperative/synergistic (Ki+1/Ki is higher than the theoretical 
value). On the contrary, if the binding of a ligand impedes the binding of the 
subsequent ligand then there is a negative cooperativity (interference), with Ki+1/Ki is 
lower than the statistical value 51-53. 
For a general case, with monovalent ligand and m-valent receptor, the 
cooperativity can be assessed through the following equations: 
! 
K
i
= k m " i +1( )/i  (1)             
! 
K
i+1
K
i
=
i m " i( )
i +1( ) m " i +1( )
 (2) 
A comprehensive example of cooperativity in biology can be found in the 
following references 54-59. 
As the binding constants of biotin in (strept)avidin are extremely high, there 
are still arguments in pro and contra concerning the cooperativity in this system. Sano 
and coworkers 60 suggested that the cooperativity of biotin binding in streptavidin 
relies on the cooperativity of dimers of streptavidin. In contrast, in 1995 Jones and 
coworkers 61 revealed that the binding of biotin to tetrameric streptavidin is 
 10 
noncooperative. This is based on their observation that the differences in affinity of 
biotin binding to subsequent streptavidin adducts fall within 0.12 kcal⋅mol-1. This 
value is too small when compared with positive cooperativity for oxygen binding to 
hemoglobin ΔΔG = -8 kcal⋅mol-1 between k1 and k4 62. Nevertheless, as the binding of 
biotin to streptavidin is extremely tight, the assessment of cooperativity is a non-
trivial task. Therefore, the cooperativity of this system remains questionable. 
1.2.3. Conclusion 
Biotin-avidin technology, based on the strong interaction between the host 
protein and a covalently bound active cofactor/ligand to biotin, is extremely useful in 
chemistry and biology for a large number of purposes. Some parameters can influence 
the affinity of biotinylated compounds in avidin: type and length of the linker, the 
nature of the cofactor and, in the case of metal complexes, also the steric hindrance of 
the non-biotinylated chelates.  
1.3. Asymmetric hydrogenation & design of artificial metalloenzymes 
In the area of enantioselective catalysis, many efforts have been made to reach 
useful applications and to meet the industry demand, culminating by achievement of 
the joint nobel prize in 2002 63-67. Asymmetric hydrogenation is a core technology in 
modern synthesis. The recent substantial expansion of this subject has given rise to 
enormous economic potential in the chemical manufacture of pharmaceutical, health 
products, agrochemicals, flavors and fragrances 68, 69. To date, many functional groups 
can be hydrogenated with high selectivity and high conversion, and scale-up is 
usually not problematic for industrial application. 
The low valent metals such as Rh, Ru, and Ir are known as the most active and 
versatile catalysts in asymmetric hydrogenations. The first indications of a potentially 
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useful ligand are catalyst productivity (TON or S/C), catalyst activity (TOF), and 
selectivity (ee). 
1.3.1. Homogeneous asymmetric hydrogenation 
1.3.1.1. Ligand design 
The first milestone of asymmetric hydrogenation was published in 1966 70, 71, 
when Wilkinson reported the preparation of RhCl(PPh3)3, for homogeneous 
hydrogenation of alkene. W. S Knowles 72 demonstrated by substituting 
triphenylphosphine with chiral phoshines, that the phosphorous atom brings the 
chirality affording efficient catalyst for the asymmetric hydrogenation of α-
phenylacrylic acid (88% (S) using camp ligand, Scheme 9). The sensational finding at 
that period was the use of camp as ligand for the production of (S)-dopa (stabilizer 
agent of parkinson disease) at industrial scale 73, 74 (Scheme 8). The finding of dipamp 
ligand (Scheme 10) improved the selectivity for the production of (S)-dopa (95 %(S)). 
 
H
OCH3HO
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H
OCH3HO
CO2H
NHAc
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OHHO
CO2H
NHAc
(S)-dopa
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Scheme 8. Industrial production of (S)-dopa (Monsanto Process) using [Rh(camp)2(COD)]+. 
 
Later on, Kagan & Dang 75 demonstrated that a chiral at phosphorous ligand is not 
necessary if a chiral bidentate ligand is used, such as C2-symmetric diphosphine 
ligand diop (Scheme 10).  
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In principle, ligands for asymmetric hydrogenation can be classified into two 
classes, monodentate ligands and bidentate ligands. For some particular cases, 
tridentate ligands may also be designed. 
Monodentate class of ligands (as shown in Scheme 9) displays some 
interesting features 76 such as being highly active in hydrogenation catalysis, able to 
achieve equal or better ee than bidentate analogues. Furthermore, monodentate 
ligands can be prepared from cheap and readily available starting material. 
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Scheme 9. First and second generations of monodentate ligand for asymmetric hydrogenation.  
 
Bidentate ligands comprising axially chiral biaryl ligands (binap family) were 
discovered by Noyori and coworkers 77 in early 80’s. Thereafter, binap became one of 
the most versatile class of chiral ligands for hydrogenations of a wide variety of 
substrates with Ru complexes 66, from activated ketones to α,β-unsaturated acids, 
allylic alcohols, and enamides 78-82. Other ligands that achieved successful application 
are biphep and biphep derivatives (Scheme 10) 83. The finding of the 
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diphosphine/diamine ligand by Noyori 84 has broadened the substrate scope of 
asymmetric hydrogenation.  
Kumada and Hayashi 85 were the first to introduce the ferrocenyl-based 
diphosphine ligands, based on the pioneering work of Ugi 86, 87 related to synthesis of 
enantiopure substituted ferrocenes. Later, Togni and Spindler 88 improved the 
performance of this ligand by introducing the second phosphino group at the 
stereogenic center of Ugi’s amine. Since then, the josiphos ligand of Solvias (Scheme 
10) is known as the most versatile and successful ligand from the ferrocenes family 89. 
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Scheme 10. Privileged ligands are in widespread use in chemical industries affording high TOF/TON 
and a highly enantioselective reduction. 
 
Burk in the early 90’s 89 designed and introduced a novel backbone – 
phospholane type ligands. The success of duphos ligands (Scheme 10) has created 
considerable activity in other laboratories and a number of interesting variants have 
been published in the last few years 90, 91.  
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Scheme 11 highlights some examples of asymmetric hydrogenation at an 
industrial scale (small scale production to pilot process) 76, 92, 93. 
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Scheme 11. Industrial scale application of asymmetric hydrogenation of several substrates using 
privileged ligands. 
 
1.3.1.2. Multiphasic media for asymmetric hydrogenation 
In order to improve the work-up in the experiments, usually the 
enantioselective hydrogenations are performed in biphasic (multiphasic) media. The 
advantage of this process, in one hand is to avoid product separation from reaction 
media, and in the other hand to allow recycling and reusing the catalysts. However in 
industrial practice, the use of multiphase media is rarely found 94.  
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1.3.2. Heterogeneous asymmetric hydrogenation 
The tremendous progress in asymmetric transformation in both homogeneous 
and enzymatic catalysis is leaving a significant gap with their heterogeneous 
counterpart. The non-trivial ligand design and the need for “sophisticated” equipment 
make the heterogeneous transformations as a major challenge for the chemists. 
However, in the past few years, some groups 95-98 have successfully designed a lab-
scale design for heterogeneous asymmetric transformations, although optimizing 
conditions are difficult to achieve.  
1.3.3. Enantioselective hydrogenation in aqueous media 
The chemical industry is under considerable pressure to replace volatile 
organic compounds that are currently used as solvents in organic synthesis. The 
toxicity, hazardous properties and expensive remediation of these solvents, notably 
chlorinated hydrocarbons, are making their use limited and even prohibitive. Thus, 
the use of “alternative – more environment friendly” solvent becomes increasingly 
important 99. Some factors that determine the “greenness” of a reaction are: E factor 
(weight of the waste/weight of the product, E > 100), V productivity (gram 
product/liter reaction medium), and solvents 100.  
Asymmetric transformation in aqueous media is becoming increasingly 
attractive as the demand for environmentally benign solvents increases. However, 
asymmetric transformation in water remains challenging. The use of sulfonated 
phosphine ligand for hydrogenation using aqueous media began in 1973 with a paper 
by Joo and Beck 101. Since then, the numbers of studies dealing hydrogenation in 
aqueous media is growing rapidly. One of some examples: Davies and coworkers 102, 
103 focused on the design of water soluble ligands, by attaching a hydrophilic group, 
 16 
such as sulfonate to binap ligand (Scheme 12) affording good ees (82% (R)) of 
reduction (Z)-α-methyl acetamidocinnamate. α-acetamidoacrylic acid and its methyl 
ester can be hydrogenated conveniently using water soluble chiraphos (ee up to 94% 
(S)) 104-106. 
R2P PR2
P-C6H4-3-SO3Na
P-C6H4-3-SO3Na
R = C6H4-4-NMe3
+BF4
-
or   C6H4-4-NHMe2
+BF4
-
binap derivative chiraphos derivatives  
Scheme 12. Structure of water-soluble binap and chiraphos, two ligands used for the enantioselective 
hydrogenation in aqueous media. 
 
Ruhrchemie/Rhône-Poulenc is the industrial process that introduced and still 
uses sulfonated triaryl phosphine ligands to afford water-soluble rhodium catalyst for 
propene hydroxylation. 
Davis and coworkers demonstrated the design of chiral-water-soluble ligand 
(binap-4SO3Na) for asymmetric hydrogenation of naproxen (Scheme 13) in supported 
aqueous-phase (SAP) yielding high ee up to 96% (S ) 107.  
MeO
COOH
MeO
COOH
Ru cat. S/C = 100
rt, H2 100 atm  
Scheme 13. Hydrogenation of (S)-naproxen in supported aqueous-phase (SAP) using [Ru(binap-
4SO3Na)(benzene)Cl]Cl catalyst. 
 
Another promising but challenging media for asymmetric hydrogenations 
include the use of alternative media such as: ionic liquids 108, 109 and supercritical CO2 
110.  
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1.3.4. Enzymes 
Linus Pauling 111 rationalized the basic principle underlying enzyme catalysis 
“enzyme increases the rate of chemical reaction by binding and stabilizing the 
transition state of its specific substrate tighter than ground state”. Enzymes are 
natural catalysts that have high specificity towards compatible substrates. Usually, 
enzymes catalyze a reaction with high TON/TOF, and require mild condition 
reactions (room temperature, neutral pH) and water as media. 
A wide variety of chemical transformations (hydrolases, lyases, isomerases, 
and ligases) 112 can be performed by natural enzymes. The active site of enzymes 
plays a determinant role in catalytic activity and selectivity. One of the most 
successful enzymes used in industry is a lipase for the production of amino acid 
(BASF) 113 (Scheme 14). 
NH2
O
O
O
NH2 HN
O
O
+ +
lipase
ee 99% (S) ee 93% (S)
+ HO
 
Scheme 14. Kinetic resolutions of racemic amino acid for production of chiral amines by lipase. 
 
This process is applicable to a broad spectrum of amines, which are of considerable 
interest as chiral building blocks or as auxiliaries for the synthesis of bioactive 
ingredients. 
In 1974, Neumann and coworkers 114 reported stereoselective hydrogenation 
using microorganisms as catalysts. Clostridium kluyveri was used to hydrogenate α,β-
unsaturated carboxylic acid and Bacillus polymyxa (NCR-9035) to obtain diols from 
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α-hydroxyketones or α-hydroxyketones and diols from α-oxo acids. In 1983, Ohta 115, 
116 demonstrated that Corynebacterium equi IFO 3730 can hydrogenate double bond 
of chalcones (Scheme 15), the conversion was reported quantitative after 3 h at 30°C. 
O
R1 R2
O
R1 R2
C. equi
3 h, 30°C
 
Scheme 15. Hydrogenation of chalcone by microorganism C. equi IFO 3730. 
 
In the area of asymmetric bioreduction, recently Faber & coworkers 117 
reported the asymmetric reduction of C=C bonds using enzymes. This reaction is 
catalyzed by enoate reductase, commonly denoted as the “old yellow enzyme” family 
(Scheme 16). Alkenes bear electron-withdrawing group (EWG = ketone, aldehyde, 
carboxylic acid or anhydride, lactone, imide or nitro). 
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3
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3
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NAD(P)H NAD(P)+
recycling
system
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H-
H+
from FMNH2
from solvent
 
Scheme 16. Asymmetric bioreduction of activated alkenes bearing an activating electron-withdrawing 
group (EWG) by enoate reductase. FMNH2: flavin cofactor. 
 
Reetz 118 demonstrated that the selectivity factor in kinetic resolution of esters 
by the lipase of Pseudomona aeruginosa (Scheme 17) could be enhanced by directed 
evolution and site directed mutagenesis. 
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Scheme 17. Hydrolytic kinetic resolution of ester by lipase. 
More recently, Bäckvall and coworkers 119-121 demonstrated that the 
combination of a catalytic racemization procedure and an enzymatic resolution could 
lead to a dynamic kinetic resolution (DKR) if the enzyme and racemization catalyst 
are compatible with one another (Scheme 18).  
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Scheme 18. Chemoenzymatic DKR of (a) secondary alcohols and (b) diols using ruthenium catalyst as 
racemization chemocatalyst; immobilized Candida antartica lipase B (CALB; Novozym 435) as 
biocatalyst and p-chlorophenyl acetate as acyl donor. 
 
With the same strategy, DKR of primary amines using enzyme and metal-
catalyst, was also successfully demonstrated 122. Temperature is an important 
parameter when planning a DKR. As the racemization is usually faster at higher 
temperatures, while enzymes undergo denaturation at elevated temperatures. 
However, it has been shown in recent years that thermostability of lipases can be 
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increased by immobilization on certain supports. In addition, immobilization also 
favors the recovery and subsequent reuse of the lipase 
Wandrey and coworkers 123 reported a double-enzyme approach (as shown in 
Scheme 19) for reduction of prochiral ketones to the corresponding secondary 
alcohols affording ee > 99%.  
CPCR
NADH NAD
FDH
O
H
HO
ee > 99%
CPCR: Carbonyl Reductase from Candida parapsilosis
FDH: Formate Dehydrogenase from Candida boidinii  
 
Scheme 19. Enzymatic reduction of prochiral ketones using double-enzyme approach. 
 
Interestingly, Faber and coworkers 124 reported a “coupled-substrate” approach 
(Scheme 20) based on the use of a single enzyme for reduction of ketones and kinetic 
resolution by oxidation of secondary alcohols (biocatalytic redox system).  
O
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Scheme 20. Biocatalytic redox system using single enzyme approach using high concentration of 
organic solvents. 
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The implementation of whole cell biocatalysts (designer cells) in 
enantioselective reduction of ketones was reported for the first time by Gröger and 
coworkers (as illustrated in Scheme 21) 125. The “tailor-made” whole-cell catalyst 
was designed for a desired asymmetric reduction: alcohol dehydrogenases (ADHs) 
with a high specific activity were chosen (an ADH from Lactobacillus kefir as R-
specific alcohol dehydrogenase and an ADH from Rhodococcus erythropolis as S-
specific). A one-plasmid strategy was applied: genes that encode the alcohol 
dehydrogenase from R. erythropolis and glucose dehydrogenase from B. subtilis were 
ligated into one plasmid (pNO14c). 
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Scheme 21. Enzymatic reduction of prochiral ketones using a double-enzyme approach. 
 
1.3.5. Comparison of enzymes vs. homogeneous catalysts 
As stated in the previous section, each class of catalyst (homogeneous or 
enzymatic) is complementary, in several features: in enantiomeric recognition, 
reactions’ repertoire, TON/TOF, optimization, tolerance to the organic solvents, and 
in second sphere of coordination. One may wonder about the possibility of creating a 
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“perfect”- hybrid catalyst combining the advantages of each class of catalysts. 
Recapitulating, the hybrid catalyst should possess advantages of both homogeneous 
and enzyme catalysts. These properties are highlighted and summarized in Table 2. 
Table 2. Comparison between enzymatic catalysis and homogeneous catalysis 
Parameters Homogeneous catalysis Enzymatic catalysis 
Substrate scope Large Limited 
Enantiomers 2 enantiomers 1 enantiomer 
Tolerance to organic solvents Excellent Poor 
Substrate concentration High Low to moderate 
MW of catalyst Low High 
TON/TOF Average High 
Optimization Chemical synthesis Genetic 
Repertoire of reaction Large Restricted 
Second sphere coordination Ill-defined Well-defined 
Reactions condition 
High temperature and 
pressure 
Room temperature and 
atmospheric pressure 
Environmental impact Hazardous Friendly 
 
 
1.3.6. Artificial Metalloproteins & Artificial Enzymes 
One of the remarkable features in the recent development of bioinorganic 
chemistry is the creation of artificial metalloprotein. This section outlines the design 
of metalloenzymes (and metalloproteins) based on the incorporation of a guest within 
host. The design and engineering of this type of metalloproteins has several 
advantages: 
 Of only 20 natural amino acids, less than half are capable of coordinating to metal 
ions. In addition, nature has only a limited repertoire of metal containing cofactors. 
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By introduction of unnatural amino acids/ non-native metal-containing cofactors into 
proteins, one can elucidate more precisely the roles of key residues important in 
protein structures and function precisely. 
 The design and engineering of metalloproteins aim at fine-tuning the protein 
properties to an unprecedented level, expanding the repertoire of protein 
functionalities, and their range of application. 
The artificial metalloproteins presented here are classified according to the nature of 
the metal fragment-host protein interaction: covalent, dative, and supramolecular. 
 
1.3.6.1. Covalent anchoring 
E.T. Kaiser 126 demonstrated for the first time that novel catalytic function 
could be created by covalent modification of an amino acid residue with appropriately 
modified coenzyme analogues. In his seminal work, it was shown that papain could 
be converted into a highly effective oxidoreductase by attaching covalently thiol 
group of cysteine residue C25 with flavins.  
Other pioneer studies in semisynthetic covalent anchoring were those of 
Distefano and coworkers 127. The attachment of Cu (II) 1,10-phenantroline complex to 
a single cysteine residue in adipocyte lipid-binding protein (ALBP) as shown in 
Scheme 22afforded high ee for the stereoselective hydrolysis of several unactivated 
amino acid ester derivatives (86% ee).  
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Scheme 22. Stereoview of ALBP-phenantroline complex (PDB: 1A18) (a); Covalent attachment Cu-
Phen complex in ALBP (b); Enantioselective hydrolysis of amino acid ester derivatives using ALBP-
Phen-Cu(II) (c) 
 
The covalent anchoring approach in artificial metalloenzymes has also been 
pursued by Reetz and coworkers 128; Mn (Salen) complexes were linked to papain 
through Michael additions of the cysteine C25 to the maleinimide-derivatized Schiff 
base (Scheme 23-A), though the catalytic results were moderate (ee less than 10%).  
Similar results were obtained in the catalytic hydrogenation using RhCl3(bis-pyridine) 
⊂ papain (Scheme 23-B). Alternatively, diphosphine (Scheme 23-D) was covalently 
attached to a serine within a lipase through phosphonate and catalyst localization was 
unambiguously established by enzyme inhibition experiments. Recently, de Vries and 
Feringa 129 reported the reduction of methyl acetamidoacrylate using the covalent 
attachment of monophosphite (Scheme 23-C) to cysteine C25 in papain. Good 
activity but no enantioselectivity was observed.  
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Scheme 23. Covalent anchoring of ligands and complexes to papain and lipase. 
 
Double-point covalent attachment of a metal cofactor in myoglobin was used 
by Lu and coworkers 130 to produce artifical metalloenzymes for the oxidation of 
thioanisole affording thioanisole sulfoxides (51% ee). A recent example of covalent 
anchoring was reported by Fontcave and coworkers 131, who linked covalently a 
tricarboxylmanganese(I)-aquo complex containing a monodentate organic ligand into 
lysozyme to generate a binuclear Ni-Mn complex.  
 
1.3.6.2. Dative Anchoring 
Kaiser and coworkers 132 demonstrated dative modification of the active site of 
an enzyme resulting in an artificial metalloenzyme with novel catalytic properties. 
Non-covalent insertion of Schiff base complexes into the apomyoglobin cavity was 
reported by Watanabe and coworkers 133. Two advantages of Schiff base complexes 
(Scheme 24) for the heme substitution are that their molecular size and coordination 
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geometry are similar to heme and that it is easy to modify the ligand size and 
hydrophobicity. Watanabe and coworkers demonstrated that the insertion of Schiff 
base complexe into apomyoglobin, after removal of protoporphyrin IX (original heme 
in myoglobin), improved catalytic reactivity in enantioselective thioanisole 
sulfoxidation albeit with moderate ee (32% (S)).  
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Scheme 24. Molecular structures of heme and Schiff base complexes (M = Cr, Mn, and Fe) used for 
incorporation in myoglobin. 
 
The native hemin of myoglobin can be reconstituted with floavohemin 
affording reductive activation of O2, mimicking P450 by dative modification. 
Myoglobin (Mb) and P450 have the same prosthetic group, protoheme IX, but bound 
dioxygen on the heme is utilized in a different way 134.  
Other examples of dative modification in the area of artificial metalloenzymes 
comprise the following reactions: oxidation 135, dihydroxylation 136, sulfoxidation 137 
and epoxidation 138, 139. Additionally, some enzymes are shown to catalyze more than 
one distinct chemical transformation, known as catalytic promiscuity, a term that has 
been introduced by Kazlauskas 140, 141. 
An antibody can be considered a unique type of host that can be tailored to 
bind desired ligands via immunization with an appropriately chosen hapten. The 
design of metal-containing hapten is a nontrivial task because the hapten should have 
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considerable hydrolytic stability under the physiological conditions during the 
immunization process. In this area, a few promising results have been obtained using 
robust porphyrin-containing haptens for immunization. 
A first example of asymmetric hydrogenation of α-acetamidoacrylic acid 
using an achiral rhodium complex embedded in the antibody was reported by Harada 
and coworkers 142 affording 98% ee (S) N-acetyl-L-alanine (Scheme 25).  
 
Scheme 25. Structure of achiral Rhodium complex used as hapten in the antibody. 
 
 
1.3.6.3. Supramolecular Anchoring 
Roelfes and Feringa 143 reported the preparation of artificial metalloenzymes 
built from two classes of ligand, which were non-covalently incorporated in DNA, for 
Diels-Alder reactions (Scheme 26). It is found that the smaller class of ligand was 
bound in a more favorable orientation affording excellent ee (up to 99% endo). This 
ligand acts both as intercalator and bidentate ligand. 
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Scheme 26. Schematic representation of the DNA-based catalytic enantioselective Diels-Alder reaction 
(operating conditions: CuII-ligand (0.3 mM), DNA (1.3 mg/mL), pH 6.5, 33% mol catalyst loading, 3 
days). 
Another example of supramolecular anchoring was reported by Watanabe and 
coworkers 144, who used ferritin to accommodate a Pd-nanoparticle (as illustrated in 
Scheme 27) used for size selective olefin hydrogenation affording better TOF than 
classic catalysts.  
 
R
O
R
O
ferritin
Pd-loaded
R = -NH2; TOF = 72 h
-1
R = -Ala-OMe; TOF = 0 h-1  
Scheme 27. Schematic structure of ferritin (adapted from PDB code: 1BFR, without any further 
modification). 
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Whitesides and Wilson 27 (Scheme 28) pioneered in 1978 the asymmetric 
hydrogenation of α-acetamidoacrylic acid using a biotinylated-Rh precursor 
embedded in avidin, affording moderate ee (41% (S)). Chan and coworkers 15 
attempted to use the same principle using other diphoshine ligands: their results 
displayed moderate enantioselectivities (up to 48% (R) and 11% (S)). After 
optimization of operating conditions (pH, pressure, temperature), the selectivity was 
improved, although ees remained moderate (up to 48% (R) and 37% (S)). 
 
Scheme 28. Enantioselective hydrogenation of α-acetmidoacrylic acid using complex [Rh(NBD)(Biot-
1)+] ⊂ WT avidin. Inset: structure of Pyrphos by Chan and coworkers 15. 
 
Inspired by Whitesides’ pioneering work, the biotin-avidin technology has 
also been successfully applied in our group for transfer hydrogenation of ketones 
catalyzed by d6-piano stool complexes 145-147.  
 
 30 
1.3.7. Mechanistic study of asymmetric hydrogenation and Michaelis-Menten 
kinetics 
1.3.7.1. Mechanistic study of asymmetric hydrogenation  
Halpern and coworkers 148 studied in detail the mechanism of asymmetric 
hydrogenation of methyl-(Z)-α-acetamidocinnamate using (R,R)-dipamp ligand. They 
proposed that there are four key steps in this mechanism as depicted in Scheme 29: 
A. Reversible binding of the substrate to the catalyst via the oxygen atom of the 
amide group and C=C bond affording rhodium-substrate complex 
B. Irreversible oxidative addition of dihydrogen to rhodium-substrate complex 
C. Irreversible migratory insertion of the C=C bond into the Rhodium-H bond 
D. Irreversible reductive elimination of the product. 
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Scheme 29. Catalytic cycle for Rh(dipamp) – catalyzed hydrogenation of methyl-(Z)-α-
acetamidocinnamate (P-P = (R,R)-dipamp, S = alcoholic solvent). 
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Only the first two steps (A and B) were experimentally observable. As the 
second step (B) is the first irreversible step, it thus dictates the enantioselectivity. 
Furthermore, these studies revealed that the major intermediate (SCmaj) , which is 
thermodynamically more stable, reacts more slowly with dihydrogen molecule than 
its minor counterpart (SCmin), thus affording minor products at the end of the catalytic 
cycle. It is noteworthy that the enantioselectivity is determined by the relative rates of 
the reaction of the diastereomer adducts with dihydrogen rather than by equilibrium 
constants for binding of the prochiral substrate to the chiral catalyst. Furthermore, it is 
found that ee decreases with increasing of H2 partial pressure.  
1.3.7.2. Michaelis-Menten Kinetics  
Traditionally, in enzymatic catalysis, Michaelis-Menten equations are used to 
assess and determine the kinetic parameters of a reaction. Leonor Michaelis and Maud 
Menten laid the foundation for enzyme kinetics as early as 1913 by proposing the 
following scheme: 
 
The reaction should follow saturation kinetics with respect to the concentration of 
substrate. The substrate concentration at half the maximal rate, (Vmax/2), is called the 
KM. For many simple reactions, KM is equal to the dissociation constant of ES 
complex. These steps could be described as follow: 
! 
K
M
=
k"1
k
1
 
Where E: enzyme; S: substrate; ES: complex enzyme-substrate, P: product and rate 
of reaction or turnover number: k2. Rate of reaction can be described as a function of 
[S], KM, and Vmax, (Scheme 30) with 
! 
V
max
= k
cat
E[ ]
0
. 
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Scheme 30.  Representation of Michaelis-Menten plot for determination of kinetic parameters. 
 
The maximum rate of reaction Vmax is always observed when the substrate 
concentration is much higher than the enzyme concentration and it is obtained when 
the enzyme is saturated with substrate. The quantity kcat/KM is a rate constant that 
refers to the overall conversion of substrate into product. The ultimate limit of the 
value is therefore set by the rate constant for the initial formation of the ES complex. 
This rate cannot be faster than the diffusion-controlled encounter of an enzyme and its 
substrate, which is 108 to 109 per mole per second. 
Donna G. Blackmond and coworkers 149, 150 stated that the kinetics of the 
hydrogenation reaction depends to the concentration of hydrogen in liquid rather than 
gas pressure, as the reaction occurs in the liquid bulk 151.  
 
1.4. Objectives of this work 
The present work focuses on the interactions of metal complex and protein in 
the context of artificial metalloenzymes based on the biotin-avidin technology. The 
cavity of the protein, which is chiral, is expected to induce chirality upon 
incorporation of the metal complexes into the protein. This interaction has been 
exploited for the investigation of catalysts for asymmetric hydrogenation. The 
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thermodynamic, kinetic and selectivity of these asymmetric hydrogenation reactions 
will be discussed.  
As for thermodynamic studies, the work focused on the design of the 
diastereopure of [Ru(Biot)2(Biot-bpy)]2+ to elucidate the enantiodiscrimination upon 
incorporation of the biotinylated complexes in the host protein, (strept)avidin. 
Determination of the binding constants was performed through CD 
spectrophotometric titrations and the data were treated using SPECFIT/32 package. 
The assessment of the cooperativity between binding sites was performed and is 
described in detail. 
Application of biotin-avidin technology is promising, but challenging. In the 
past few years, our group has demonstrated that incorporation of achiral/chiral spacer-
biotin conjugated-Rh complexes in the (strept)avidin generated highly (R)-selective 
and (S)-selective artificial hydrogenases. For this thesis, progress focused on the 
chemogenetic optimization of second-generation artificial hydrogenases. The chapter 
is devoted to describe in the first part: results from saturation mutagenesis in position 
S112 and in the second, results from a single (and double) point mutation of other 
amino acid residues in the host protein. 
Organic solvent tolerance is known to be a major problem in the area of 
enzymatic catalysis. Another aim of the thesis was to investigate whether the new 
class of the artificial hydrogenases may give an improved resistance towards organic 
solvents than the first generation. 
In the present work, a straightforward protocol to immobilize the artificial 
hydrogenase by using biotin-sepharose was proposed. This protocol was inspired by 
the fact that, first, (strept)avidin has four binding-sites and, second, when varying the 
occupancy of biotinylated-complex with respect to the protein, 1–3  occupancies of 
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binding site does not affect the catalytic result significantly (1-2% lower ee was 
observed) 152, 153. By saturating biotin-sepharose (wet beads) with streptavidin, only 
one binding site is occupied on average, allowing the rest of binding sites to attach the 
metal precursor for performing heterogeneous/immobilized catalysis.  
Finally, the kinetic study of asymmetric hydrogenation using Michaelis-
Menten approach was also carried out. To build Michaelis-Menten equations, a series 
of individual kinetic experiments with varying the concentration of substrates, were 
performed and will also be described. 
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2. THERMODYNAMIC STUDY OF INCORPORATION RUTHENIUM 
BIOTINYLATED COORDINATION COMPLEXES WITHIN 
(STREPT)AVIDIN USING CD SPECTROSCOPY 
 
2.1. Introduction 
The incorporation of biotin ⊂ (strept)avidin  has been studied extensively 
since three decades. In this context, the binding constant of biotinylated compounds 
within (strept)avidin plays an important role. To date, only few reports have been 
issued for the determination of binding affinities, and even less to study the 
cooperativity of binding of biotinylated ligands in (strept)avidin. In this chapter, we 
present a straightforward determination of binding constants of biotinylated 
compounds in (strept)avidin using CD spectroscopy. The assessment of the 
cooperativity of incorporation biotinylated compounds within (strept)avidin will be 
presented and discussed.   
 
2.2. Synthesis of biotinylated coordination complexes: [Ru(bpy)2(Biot-bpy)]2+ 
(1) 
The synthesis of biotinylated bipyridine ligand Biot-bpy (4) was achieved by 
mixing equimolar amounts of biotinylated ethylenediamine (2) 154 with the activated 
ester (3) 155 in the presence of triethylamine in DMF. rac-[Ru(bpy)2(Biot-bpy)](PF6)2 
(rac-1(PF6)2) 156 was achieved by refluxing [Ru(bpy)2Cl2] in the presence of a slight 
excess of Biot-bpy (4), followed by precipitation with NH4PF6 (Scheme 31). 
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Scheme 31. Synthesis of Biot-bpy (4) and formation of the corresponding racemic coordination 
complex rac-1(PF6)2. 
 
The preparation of diastereopure Λ-[Ru(bpy)2(Biot-bpy)]2+ (Λ-1) was 
achieved using von Zelewsky’s procedure 157, 158. Refluxing of Λ-[Ru(bpy)2(py)2][(-)-
O,O’-dibenzoyl-L-tartrate] with Biot-bpy (4) in ethyleneglycol-water mixture in the 
dark affords Λ-[Ru(bpy)2(Biot-bpy)]2+ (Λ-1). The diastereomeric purity of 
biotinylated complex Λ-1 was assessed by subjecting a quantity of crude sample to 
ion exchange chromatography (Sephadex C-25) using potassium nitrate (0.05 M, pH 
= 5.0) as eluent. The entire elution peak was collected in three fractions; each of these 
was analyzed by UV-Vis and CD spectroscopy. Plotting the ratio of the signals (UV-
Vis/CD) for each fractions results in a horizontal line, thus suggesting that the entire 
elution peak is diastereopure. 
These steps are summarized in Scheme 32. 
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Scheme 32. The synthesis of diastereopure biotinylated coordination complex Λ-1 using von Zelewsky’s procedure. Inset: CD spectra of diastereopure Δ-1 and Λ-1.
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2.3. Titration experiments 
The activity of (strept)avidin was determined using Gruber’s protocol 159 
based on the fluorescence quenching of biotinylated fluorescein upon incorporation in 
(strept)avidin. 
In the first attempt, the determination of binding constants was performed by 
titrations of apo-protein with rac-1. The titrations were carried out at 25°C and 
buffered at pH = 7 aqueous medium (KH2PO4/Na2HPO4). The ellipticity changes 
induced by the incremental addition of a rac-[Ru(bpy)2(Biot-bpy)]2+ (rac-1) solution 
in 5.0 µL aliquots (0.25 equiv) were monitored up to 6.0 equiv vs. the tetrameric 
protein in 250−500 nm range by circular dichroism (CD) spectroscopy. 
The CD spectra resulting from the titration of rac-[Ru(bpy)2(Biot-bpy)]2+ (rac-1)  
with avidin are depicted in Figure 1. 
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Figure 1. CD titration profile obtained for the addition of aliquots of rac-1 to avidin. Inset: titration 
profile monitored at 313 nm (I = 0.15 M; KH2PO4/Na2HPO4; pH = 7.00; T = 298.1 K). 
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Similar results were obtained with streptavidin 156. Figure 1 suggests that the 
biotinlyated coordination compound can occupy four binding sites of (strept)avidin. 
Since the biotinylated guest is racemic, the appearance of a strong band centered at 
313 nm can be attributed to an induced CD signal resulting from second coordination 
sphere interaction between the host-protein and the guest (rac-1). 
 
2.4. Determination of stability constants 
In order to determine the stability constants, the spectroscopic data were 
analyzed using SPECFIT/32 package 160-162 with a theoretical model with up to four 
binding constants. However, this attempt failed, as reflected by the lack of 
convergence in the fitting procedure. This is probably due to the presence of both 
diastereomers of the biotinylated coordination complexes within a single tetrameric 
(strept)avidin. 
The following simplified model points out the complexity of this system, taking into 
account the following assumptions: 
i.) A second guest molecule enters exclusively in trans-position to the first guest. 
ii.) The two remaining free binding sites in (strept)avidin are identical. 
iii.) The affinity of the guest depends on the presence or absence of a guest in an 
adjacent binding site. 
This procedure affords 14 different binding constants to be fitted for rac-
[Ru(bpy)2(Biot-bpy)]2+ ⊂ (strept)avidin. This situation is summarized in Scheme 33. 
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Scheme 33. Possible binding events for a racemic guest in a tetrameric host protein. 14 binding 
constants are generated from the interactions of racemic mixture with the homotetrameric protein. (•) 
and  (o) are diastereomers. 
 
In order to reduce the number of unknown binding constants, the 
spectrophotometric titrations were repeated with the diastereopure biotinylated 
ruthenium complexes (Δ-1 and Λ-1). The spectra of these titrations are depicted in the 
Figures 2-5. As expected, considering the structural similarity of avidin and 
streptavidin, both titration spectra closely resemble each other (Figure 2 vs. Figure 3, 
and Figure 4vs. Figure 5). 
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Figure 2. CD titration profile obtained for the addition of aliquots of Λ-1 to streptavidin. The red lines 
correspond to the CD spectra of the diastereopure biotinylated complex (Λ-1) in the absence of 
streptavidin (I = 0.15 M; KH2PO4/Na2HPO4; pH = 7.00; T = 298.1 K). Inset: titration monitored at 324 
nm. 
 
Upon inspection of the spectra, one can observe that both apo-proteins show 
weak absorption bands occurring below 300 nm with a positive Cotton effect 
ascribing to tryptophan-centered transitions, both apo-proteins are spectroscopically 
silent above 310 nm. Upon addition of the Λ−1  diastereomer, a negative band at 280 
nm progressively appears accompanied by a more intense and positive signal centered 
around 300 nm that tails out in the visible region as broad, albeit much weaker. 
Ellipticity features a negative (340−455 nm) and, at higher wavelengths, a positive 
(455−500 nm) Cotton effect.  
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Figure 3. CD titration profile obtained for the addition of aliquots of Λ-1 to avidin. The red lines 
correspond to the CD spectra of the diastereopure biotinylated complex (Λ-1) in the absence of avidin 
(I = 0.15 M; KH2PO4/Na2HPO4; pH = 7.00; T = 298.1 K). Inset: titration monitored at 290 nm. 
 
As the titration proceeds, the CD-induced ellipticity bands undergo subtle 
morphological changes in the UV region, without showing sharply defined 
isodichroic points. This behavior is best exemplified by the steady intensity increase 
of the low- at the expense of the high-energy component of the positive envelope 
peaking at 308 nm (ca. 10 nm shift) at the end of the titration of (strept)avidin. The 
non-monotonic variation of the ellipticity measured at selected wavelengths further 
confirms the one-by-one sequential uptake of the biotinylated ruthenium 
tris(bipyridine) complexes (Δ-1 and Λ-1) by the protein. 
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Figure 4. CD titration profile obtained for the addition of aliquots of Δ-1 to streptavidin. The red lines 
correspond to the CD spectra of the diastereopure biotinylated complex (Δ-1) in the absence of 
streptavidin (I = 0.15 M; KH2PO4/Na2HPO4; pH = 7.00; T = 298.1 K). Inset: titration monitored at 
329.5 nm. 
 
Despite opposite Cotton effects and some similarities in the general 
morphology, interestingly the spectra pertaining for a given host-protein (avidin and 
streptavidin) to both diastereomer Λ-1 and Δ-1 are not reflecting the similar effect of 
induction (as shown in Scheme 2, the CD spectra of Λ-1 and Δ-1 are superimposable 
to the mirror image of each other).  
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Figure 5. CD titration profile obtained for the addition of aliquots of Δ-1 to avidin. The red lines 
correspond to the CD spectra of the diastereopure biotinylated complex (Δ-1) in the absence of avidin 
(I = 0.15 M; KH2PO4/Na2HPO4; pH = 7.00; T = 298.1 K). Inset: titration monitored at 324 nm. 
 
The major differences appear in the region around 300 nm. Whereas the 
positive feature is clearly resolved into two components in the case of Λ-1 
diastereomer (Figure 2 and Figure 3), for the Δ-1 complex (Figure 4 and Figure 5), 
the negative feature evidences no visible splitting. In addition, development of a much 
weaker band with positive Cotton effect at 331 nm is observed only for the binding of 
Δ-1 diastereomer. This electronic transition is characteristic for complex formation 
since it is absent in the spectrum of free Δ-1. 
Each data sets of titration were imported into the SPECFIT/32 package. Factor 
analyses were calculated from preliminary examination in SPECFIT/32, representing 
the approximate number of absorbed components present in the solution. This can be 
achieved via singular-value decomposition (SVD) procedure, which is integrated in 
the software package. The spectroscopy data, comprising 27 spectra and 501 
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distributed wavelengths can be extracted to not more than five eigenvalues without 
losing information other than instrumental noise. The overall binding constants were 
subsequently refined by nonlinear least squares using Marquardt’s algorithm 163. 
 
Considering that both streptavidin and avidin are homotetrameric proteins 
constructed from identical, single domain subunits consisting of eight-stranded, 
antiparallel β-barrels, the most obvious chemical model to be considered should 
include six absorbing species, namely the four inclusion complexes (x = 1 − 4) in 
addition to both reactants. However, all attempts to determine these four stability 
constants failed, as reflected by the lack of convergence of the fitting procedure. The 
rough overview of the success of the determination of binding constants may be 
obtained by comparing the theoretical number of component existing in the system 
with the significant factor analysis obtained from Evolved Factor Analysis (EFA). 
As an example, the eigenvalues/significant factor analysis obtained after 
importing the data using SPECFIT/32 package for Δ-1 ⊂ streptavidin system are 
depicted in Figure 6: 
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Figure 6. Eigenvalues/factor analysis obtained from SPECFIT/32 package for titration data of Δ-1 ⊂ 
streptavidin system (EV = eigenvalue(s)). 
 
A critical examination to define the number of component present in the 
system is therefore essential. From Figure 6, we speculate for the first attempt to take 
into account only the first 5 eigenvalues being introduced in the equilibrium model. 
This procedure yields 3 equations of equilibrium by excluding the first equilibrium; 
the results of this iteration were compiled in the Table 3. For the second attempt, we 
consider that there are six absorbant species, representing the complete 4 equilibrium 
equations, however the nonlinear least square minimization failed. We reasoned that 
the sixth eigenvalue is less significant compared to the systematic equipment error.  
The encountered numerical difficulties are a direct consequence of a very 
shallow, badly defined error hypersurface and were systematically associated with 
divergence of the first equilibrium constant β1. 
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On the basis of the lack-of-fit parameter σ expressed as the residual standard error 
and by the physical meaning of the calculated CD spectra pertaining to each species, 
only the model with three inclusion complexes was evaluated (x = 2 − 4). 
A comparison of the calculated and experimental spectra recorded for the apo-
(strept)avidin and complex was of particular value in discarding models with similar 
σ values that were not statistically different from each other at the 95% probability 
level according to a Fischer−Snedecor F-test. As expected, the optimal fit was 
obtained after excluding β1 from the set of refined constants. 
The estimations of the stepwise binding constants are summarized in Table 1, 
together with their standard deviations derived from the variance/covariance matrix. 
The refined equilibrium constants log βx are highly correlated with correlation 
coefficient systematically exceeding 0.99, while stepwise constants (log Kx) are less 
correlated (the highest correlation coefficient in the range of 0.75, found between log 
K1K2 and log K3). 
Table 3. Summary of refined binding constants between [Ru(bpy)2(Biot-bpy)]2+ (1) and (strept)avidin 
using a three equilibrium model.  Standard deviations are given in parenthesis. 
Host-guest complex log K1K2 log K3 log K4 
(Δ-[Ru(bpy)2(Biot-bpy)]2+)⊂avidin 15.1(5) 6.8(2) 6.7(1) 
(Λ-[Ru(bpy)2(Biot-bpy)]2+)⊂avidin 15.7(3) 7.2(1) 7.4(1) 
(Δ-[Ru(bpy)2(Biot-bpy)]2+)⊂streptavidin 18.9(9) 8.9(2) 8.4(2) 
(Λ-[Ru(bpy)2(Biot-bpy)]2+)⊂streptavidin 18.8(6) 9.5(2) 8.1(1) 
a I = 0.15 M (KH2PO4/Na2HPO4), pH = 7.00 , T = 298.1 K. 
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The refined CD spectra corresponding to each absorbing species for the 
investigated systems are displayed in Figure 7 (for Λ-1 ⊂ avidin) and in Figure 8 
(for Δ-1 ⊂  streptavidin). For all theses cases, molar CD coefficient Δε values 
calculated for the apo-proteins and free diastereopure complexes are in excellent 
agreement with the experimentally measured values. In addition, almost perfect 
mirror image coincidence was found for the computed spectra of both Δ-1 and Λ-1 
diastereomers, providing further confidence in the refinement results.  
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Figure 7. Refined CD spectra for each absorbing species for (Λ-1)x ⊂ avidin, x = 0: red line, x = 2: 
green line, x = 3: brown line and x = 4: violet line. For comparison, the measured spectra for the host 
protein and for the biotinylated guest Λ-1 are displayed as open circles and full triangles respectively, 
overlaid with the corresponding refined spectra (thin lines). 
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Figure 8. Refined CD spectra for each absorbing species for (Δ-1)x ⊂ streptavidin, .x = 0: red line, x = 
2: green line, x = 3: brown line and x = 4: violet line. For comparison, the measured spectra for 
streptavidin and for Δ-1 are displayed as open circles and full triangles respectively, overlaid with the 
corresponding refined spectra (thin lines). 
 
The species distribution diagram for the four investigated systems are depicted 
in Figure 9. A close view to these distribution diagrams, avidin showed a more 
regular fashion in the formation of the complexes. Up to a two-fold of Ru-complex 
(Δ-1 or Λ-1), the presence of bis-species is pre-dominant in the solution. However, in 
streptavidin, the competition between bis- and tris-species was already observed from 
the beginning of the titration (this observation is clearly shown for (Λ-1)x ⊂ 
streptavidin system, Figure 9(a)). Though, this indication is still questionable if this 
phenomenon could be related to the cooperativity of the binding sites. 
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Figure 9. Species distribution diagram for (Λ-1)x ⊂ streptavidin (a); (Δ-1)x ⊂ streptavidin (b); (Λ-1)x ⊂ 
avidin (c) and (Δ-1)x ⊂ avidin (d) .x = 0: blue line, x = 2: red line, x = 3: green line and x = 4: brown 
line. 
The attempts to determine the first binding constants K1, including addition of 
smaller aliquots of biotinylated complex 1 as well as titration of biotinylated 
complexes with aliquots of (strept)avidin failed. To rationalize this observation, one 
may put forward the following arguments: 
i.) The impossibility to identify the (Λ-1/Δ-1) ⊂ (strept)avidin complex during 
the titration is a direct consequence of very similar spectra signatures of both 
mono and bis-species making them indistinguishable by CD spectroscopy. 
This argument is plausible considering the high similarity of the four binding 
pockets found in the crystal structure of both proteins in the loaded and 
unloaded state.  
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ii.) A strong cooperativity of the formation of the bis-species (Δ-1 or Λ-1)2 ⊂ 
(strept)avidin, so that the concentration of the mono-species (Δ-1 or Λ-1) ⊂ 
(strept)avidin at any stage of titration remains below the detection limit of the 
CD spectrophotometer. 
 
2.5. Assessment of the cooperativity: creation & simulation of artificial data 
A quantitative assessment of cooperativity for the four systems under 
investigation is complicated by the errors associated with the equilibrium constants 
and most importantly by the fact that K1 remains experimentally inaccessible. It 
proved particularly intricate to circumvent this difficulty just by tuning the titration 
conditions while maintaining the measured signal below the saturation level of the 
CD detector. Although the spectral contribution of the mono-adduct species to the 
overall measured CD signal is similar or even below the instrumental noise level, 
exclusion of the first equilibrium from the chemical model raises some important 
concerns from a computational standpoint.  
To appreciate the extent of the bias on the refined values of the equilibrium 
constants introduced when the formation constant of a minor species is ignored, a 
series of artificial data sets with known values of binding constants and molar CD 
absorption coefficients were generated at different, but constant noise levels using the 
simulation routine implemented in SPECFIT/32 package. 
The conditions were chosen so as to reproduce accurately the actual titration 
conditions. We focused this examination for Δ-1 ⊂ streptavidin system. The refined 
spectra and rounded-off values of the equilibrium constants corresponding to the free 
components and inclusion species displayed in Figure 8 were used as input for each 
simulation. As far as the uncharacterized mono-species is concerned, its molar CD 
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absorption Δε were arbitrarily set to half the molar CD absorption coefficient 
calculated for the bis-species (Δ-1 or Λ-1)2 ⊂ (strept)avidin (Figure 10), which seems 
a reasonable assumption considering the similar spectral morphologies displayed by 
the three inclusion complexes (for Δ-1 species, while considering only the similarity 
of the tris- (Λ-1)3 ⊂ (strept)avidin and (Λ-1)4 ⊂ (strept)avidin for Λ-1 species). 
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Figure 10. Fixed CD spectra used to generate the artificial data sets. For each absorbing species for (Δ-
1)x ⊂ streptavidin. x = 0: violet line, x = 1: green line, x = 2: red line, x = 3: blue line and x = 4: black 
solid line. The spectrum of Δ-1 is displayed as a dotted black line. 
 
A global analysis of the artificial data sets, first with the full model and then with the 
sub-model ignoring the formation of the minor mono-species, allow one to check the 
robustness of the minimization algorithm with increasing random noise. 
Referring to these calculations, unbiased estimates of the four association 
constants in full agreement with the true values were computed as long as the noise 
level remained below 0.001%, although the concentration of Δ-1 ⊂ streptavidin does 
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not exceed 1.5% throughout the titration (Figure 11). With increasing noise level 
(~0.1%), the same refinement difficulties as those experienced for the real data were 
encountered, leading to exclude β1 from the model.  
 
Figure 11. Species distribution diagram calculated for the above mentioned conditions (For each 
absorbing species for (Δ-[Ru(bpy)2(Biot-bpy)]2+)x ⊂ streptavidin ((Δ-1)x ⊂ streptavidin). x = 0: black 
solid line, x = 1:red line, x = 2: blue line, x = 3: green line  and x = 4: black dotted line. The fraction of 
the (Δ-1) ⊂ streptavidin species does not exceed 1.5%. 
 
Interestingly, the most important outcome was obtained when the simulated 
data were analyzed with the incomplete model. As long as the spectral contribution is 
significantly greater than the random noise level, a sizeable but approximately 
constant bias close to 0.25 logarithmic units affects the refined β2, β3, and β4 
equilibrium constants, while the visual examination of the residual plot evidences 
systematic trends. More surprisingly, the deviation of the parameter estimates from 
their nominal values become larger and larger as the noise level increases and the 
contribution of the minor species is vanishing in the spectral background. 
Unpredictable errors that could be larger than one order of magnitude were obtained 
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for the noisiest data sets (0.1% random noise), while the residues were approximately 
randomly distributed around zero. 
Table 4. Influence of the random noise level on the association constant values refined either for the 
complete (equilibrium 1 to 4) or partial (equilibrium 2 to 4) modelsa 
Noise level  0% 0.001% 0.01% 0.1% 0.2% 0.5% 
Nb. of factors 5 5 5 4 4 3 
4 equilibrium model 
log β1 8.002(3) 8.01(3) 8.2(2) 8.2(8) < 0b <0b 
log β2 19.0000(5) 19.000(5) 19.00(5) 19.1(3) 18.7(4) 20(1) 
log β3 28.0000(7) 28.000(7) 28.00(7) 28.2(4) 27.7(5) 30(1) 
log β4 36.0000(9) 36.000(9) 36.00(8) 36.2(5) 35.7(5) 38(1) 
σ 2.337 × 10–5 2.286 × 10–4 2.27 × 10–3 2.207 × 10–2 2.843 × 10–2 1.1 × 10–1 
Δθmin/max (m°) ± 2.3 × 10–4 c ± 2.3 × 10–3 c ± 2.3 × 10–2 c ± 2 × 10–1 c ± 5 × 10–1 c ± 1 c 
3 equilibrium model 
log β2 19.2(1) 19.2(2) 19.2(2) 19.2(4) 19.2(4) 21(1) 
log β3 28.2(2) 28.2(2) 28.2(2) 28.3(5) 28.2(5) 30(1) 
log β4 36.2(2) 36.2(2) 36.2(2) 36.3(5) 36.3(6) 39(1) 
σ 7.240 × 10–3 7.363 × 10–3 7.837 × 10–3 2.431 × 10–2 2.972 × 10–2 1.157 × 10–2 
Δθmin/max (m°) –0.03/0.075 d –0.03/0.075 d –0.03/0.075 d ± 2 × 10–1 c ± 5 × 10–1 c ± 1 c 
a σ : residual standard deviation; Δθmin/max : range of the residual ellipticities expressed in millidegrees. 
b The refinement procedure converges but β1 is poorly defined and becomes negative (multiple 
minima). The calculated spectra become unrealistic although the estimates of β2–β4 are well defined 
and unique. c The residues are randomly distributed around zero. d The plot of residues shows 
systematic trends.  
 
Pertinent results of the singular value decomposition (number of significant 
eigenvalues) and subsequent nonlinear least-squares refinement of the artificial data 
sets to which a constant noise level has been superimposed, are summarized in Table 
4. As can be seen in Table 3 and Table 4, if the standard error in the ellipticity 
measurements is within < 0.1%, as it is the case in all experiments carried out in the 
present work, it is then safe to trust that the maximal concentration of mono-adduct 
(Δ-1 or Λ-1) ⊂ (strept)avidin does not exceed 4% during the entire titration.  Most 
importantly, this higher limit is a sufficient criterion to assess the cooperative 
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formation of the bis-biotinylated adduct (Δ-1 or Λ-1)2 ⊂ (strept)avidin starting from 
the apo-protein.  
It has therefore to be concluded that the occurrence of the minor species 
throughout a single titration results not only in poorly defined spectra and equilibrium 
constants for those species, but more importantly, the entire global nonlinear least 
squares analysis fails to produce reliable precise estimates of the unknown parameters 
corresponding to the major species. The effective rank deficiency evidenced by the 
singular value decomposition is a direct consequence of the unavoidable experimental 
noise. Thus, the values reported in Table 3 that pertain to the analysis of the 
experimental CD spectra with only three equilibria, should be considered as 
approximate and spoilt by systematic errors at least as large as the standard errors 
returned by the Marquardt procedure (bias about 0.25 logartihmic units affects the 
refined β2, β3 and β4). On the basis of this observation, the formation of the bis-species 
occurs with strong cooperativity, precluding the determination of the first binding 
constant K1. 
As comparison between host-proteins- streptavidin and avidin, in terms of 
binding constants: an enhanced overall stability constant when streptavidin is 
employed as the host protein. We reasoned that this may be due to Coulomb/repulsion 
interactions of streptavidin (pI = 6.4). Moreover, since streptavidin has a deeper 
binding pocket compared to avidin, this cavity seems to facilitate stabilizing the 
conformation of the complexes in the biotin binding pockets. Interestingly, in terms of 
chiral discrimination, avidin displays a modest preference for Λ-1, while streptavidin 
binds nearly indiscriminately both Δ-1 and Λ-1. Considering the large standard 
deviations, this last conclusion is subject to caution however.  
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Having investigated the discrimination of biotinylated coordination 
compounds upon incorporation within (strept)avidin, in the next chapter we will 
present the application of biotin-avidin technology in the area of artificial 
metalloenzymes.
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3. APPLICATION OF BIOTIN-AVIDIN TECHNOLOGY IN THE DESIGN 
OF ARTIFICIAL HYDROGENASES: COMBINATORIAL APPROACH 
AND KINETIC STUDY 
3.1. Introduction 
Inspired by Whitesides’ early report 27, our group has demonstrated that 
incorporation of a biotinylated-diphosphine Rh complex, embedded in the active site 
of either avidin or streptavidin can afford artificial hydrogenases 21, 22, 26, 152, 164-166. 
The previous studies by Dr. A. Loosli 22, 156 revealed that incorporation of 
biotinylated-diphosphine Rh complex to (strept)avidin yields a quantitative 
incorporation guest ⊂ host (estimated binding constant is 107 M-1). It is thus clear that 
the biotinylated compounds occupy the same binding pocket with a significantly 
reduced affinity as native biotin (Ka = 1014 M-1). 
Despite all efforts (computer calculation, kinetic experiments, and so forth), 
nowadays it still remains difficult to predict the outcome of a metal-catalyzed 
enantioselective reaction. As described by Knowles 167: 
“Since achieving 95 % ee only involves energy differences of about 2 kcal, which is 
no more than the barrier encountered in a simple rotation of ethane, it is unlikely that 
before the fact one can predict what kind of ligand structures will be effective”. 
To get round the difficulty of predicting enantioselectivity, asymmetric 
catalysis relies more and more on combinatorial approach to optimize the selectivity 
of new catalysts. With the same spirit, our group relies by both chemical and genetic 
strategies. Chemical optimization consists in varying the spacer (length, 
achiral/enantiopure, aliphatic/arylic) between a biotin anchor and a diphosphine 
moiety, whereas the genetic optimization relies on modifying the amino acid residues 
responsible for the interaction with the metal catalyst. 
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Initial studies focused on a chemogenetic optimization relying on the design of 
achiral amino acid spacers-ligand and saturation mutagenesis in position S112X. It 
was shown that the ligand scaffold plays a critical role on the performance of the 
resulting artificial hydrogenases 21. In addition, the reaction conditions such as: 
solvent, counter ion, added salts, have a significant and unpredictable influence on the 
enantioselectivity 168. These weak interactions between catalyst and its non-bonded 
environment are commonly referred to second coordination sphere interactions 21. 
General trends obtained from the previous studies are as follows: combination 
of achiral spacer and twenty streptavidin isoforms revealed that chemical optimization 
creates more diversity than genetic counterpart (Table 5, entry 1-7) 165. Introduction 
of enantiopure spacer (natural α-amino acids) in combination with WT streptavidin 
resulted artificial hydrogenases with increased organic solvent tolerance and 
improved (S)-selectivity (Table 5, entry 11-13) 22. The selected results from initial 
studies are collected in Table 5. 
Table 5. Numerical summary of previous results of catalytic experiments using artificial hydrogenases. 
Entry Ligand Protein ee[a] N-
AcPhe 
Conv. N-
AcPhe 
ee[a] N-
AcAla 
Conv. N-
AcAla 
1[c] Biot-1 WT Sav 93 84 94 quant. [b] 
2[c] Biot-1 S112A 94 94 93  quant. [b] 
3[c] Biot-1 S112G 94 77 93 quant. [b] 
4[c] Biot-4meta-1 S112K -88 89 -63 quant. [b] 
5[c] Biot-4meta-1 S112R -86 71 -63 quant. [b] 
6[c] Biot-31-2 S112Y -42 10 -55 quant. [b] 
7[c] Biot-34-2 S112Q 92 77 87 quant. [b] 
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8[d] Biot-(R)-Phe-1 WT Sav 64 quant. [b] 66 quant. [b] 
9[d] Biot-(S)-Phe-1 WT Sav -64 88 -73 quant. [b] 
10[d] Biot-(S)-Pro-1 WT Sav 23 quant. [b] 23 quant. [b] 
11[d] Biot-(R)-Pro-1 WT Sav -91 quant. [b] -86 quant. [b] 
12[d] Biot-(R)-Pro-1 
(45%DMSO) 
WT Sav -86 94 -87 quant. [b] 
13[d] Biot-(R)-Pro-1 
(biphasic EtOAc) 
WT Sav -87 85 -86  90 
[a]ee in %, positive ee values in favor of the (R)-enantiomer, negative ee values in favor of the (S)-
enantiomer; [b]quantitative; [c]according reference 165; [d]according reference 22; N-AcPhe = N-
acetamidophenylalanine, N-AcAla = N-acetamidoalanine. 
 
The next section of this chapter highlights the chemogenetic optimizations of 
the second generation of artificial hydrogenases using biotin-avidin technology. The 
chemogenetic optimization is divided into two strategies: combination of chiral  
spacers with saturation mutagenesis in position S112X and combination of both chiral 
and achiral spacers with single/double point mutation. The design of the new class of 
ligands using non-natural α-amino acids will be described as well as the results of 
catalytic experiments. This new class of ligands has proven to be highly tolerant 
towards organic solvents. The results of enantioselective hydrogenation using 
immobilized artificial hydrogenases will be presented and followed by a detailed 
kinetic study using Michaelis-Menten model. 
 
3.2. Chemo-Genetic optimization 
In the preliminary study, Dr. Myriem Skander 22, 168 had identified that the 
introduction of natural α-amino acids as spacer displays some interesting features: 
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protein free precursors afforded little enantioselectivity (ee < 10%) and high tolerance 
towards organic solvents (up to 45% organic solvent content). Proline and 
phenylalanine were selected for this purpose. We reasoned that the phenylalanine 
spacer may display stabilizing π-π stacking effects upon interaction with the 
hydrophobic (strept)avidin binding pockets, which possess four of five aromatic 
residues for streptavidin and avidin, respectively. 
The studies presented herein focus on incorporation of enantiopure amino acid 
spacers (natural and non-natural). For screening purposes, the standard enamides for 
enantioselective hydrogenation were selected. A general scheme is presented in 
Scheme 34. 
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Scheme 34. Second-generation artificial hydrogenases based on the biotin-avidin technology for the 
reduction of N-acetamido dehydroaminoacids. The host protein ((strept)avidin, violet) displays high 
affinity for the anchor (biotin green); introduction of an enantiopure α-aminoacid spacer (blue), 
combined with a flexible diphosphine ligand (red) allows to chemically optimize both the activity and 
the selectivity. Site-directed mutagenesis further enables a genetic optimization of the host protein to 
afford enantioselective artificial hydrogenases. 
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3.2.1. Saturation mutagenesis at position S112X combined with enantiopure α-
aminoacid spacers 
On the basis of docking studies, it was found that position S112 is situated in 
proximity of the metal center (for systems bearing a short spacer). It was thus 
interesting to perform saturation mutagenesis at this position affording twenty 
streptavidin isoforms. Furthermore, as introduction of proline and phenylalanine 
residues displayed interesting features, we proceeded to screen other enantiopure α-
amino acid spacers. As proline spacer afforded the highest (S)-selectivity, a proline 
analog was then chosen as spacer in order to investigate the role of the ring size in 
catalytic performance. For this purpose, we chose a pipecolinic acid as “expanded” 
proline. In addition, glutamic acid 5-benzyl ester was chosen because it bears 
different properties compared to previously studied amino acids, proline and 
phenylalanine, spacers. The synthetic pathway for preparation of these new ligands 
was very similar to the previous ones (the detailed synthetical pathways are presented 
in Chapter 5). 
 The performance of the extended chiral spacer ligands in the absence of the 
(strept)avidin was tested first. In all cases, the control experiments revealed that the ee 
for the reduction product did not exceed 10% (Table 6, entries 12-13). The structure 
of the ligands and typical reaction conditions are displayed in Scheme 35. 
 62 
H
N
O
HN NH
S
O
O
H H
N
PPh2
PPh2
Biot–(R)– and (S)–Phe–1
N
HN NH
S
O
O
H H
PPh2
PPh2
O N
Biot–(R)– and (S)–Pro–1
CO2H
NHAc
CO2H
NHAcPh
+
H2 (5 bar) 0.1 M MES buffer (pH 5.5)
room temperature, 15 hours CO2H
NHAc
CO2H
NHAcPh
+
H H
1.0 mol % ligand
0.9 mol % [RhCOD)2]BF4
0.33 mol % (strept)avidin
N-AcAla N-AcPhe
50 50
H
N
O
HN NH
S
O
O
H H
N
PPh2
PPh2
Biot–(R)– and (S)–Glu5-Bz–1
N
HN NH
S
O
O
H H
PPh2
PPh2
O N
Biot–(R)– and (S)–Pip–1
OO
 
Scheme 35. Structure of biotinylated ligands and standard operating conditions for the hydrogenation 
of a cocktail mixture containing α-acetamidoacrylic acid and α-acetamidocinnamic acid (50 
equivalents of each with respect to the biotinylated ligand). 
 
The results of the hydrogenation using eight chiral-spacer ligands and twenty 
isoforms of streptavidin are collected and presented in fingerprint display allowing 
rapid identification of the trends (Scheme 36). The results of catalytic experiments 
using single and double point mutations will be discussed in section 3.2.2. 
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Scheme 36. Fingerprint display of the results for the chemogenetic optimization of α-acetamidoacrylic 
acid (top triangle) and α-acetamidocinnamic acid (bottom triangle). Combination S112P with Biot-(R)-
Pip-1, Biot-(S)-Pip-1, Biot-(R)-Glu5-Bz-1 and Biot-(S)-Glu5-Bz-1 was not tested. 
 
Inspection of the fingerprint reveals several interesting trends. 
 The absolute configuration of the aminoacid spacer by-and-large determines the 
absolute configuration of the reduction product: Biot–(R)-Pro–1 and Biot-(R)-Pip-1 
strongly favor formation of (S)-reduction products, while Biot–(S)-Pro–1 and Biot–
(R)-Phe–1 produce preferentially (R)-reduction products, Biot–(S)-Pro–1 produces 
moderate selectivities (10-30% ee). Interestingly, Biot–(S)-Phe–1, Biot-(S)-Glu5-Bz-1, 
Biot-(R)-Glu5-Bz-1, and Biot-(S)-Pip-1 give more diversity (Figure 12), the reduction 
products vary from high (S)-enantiomer to (R)-enantiomer depending on the 
streptavidin isoform.  
 Compared to the phenylalanine and proline linkers, the introduction of pipecolinic 
acid and glutamic acid 5-benzyl ester residues afforded substrate selective artificial 
hydrogenase (high activity towards smaller substrate). For example, combination of 
Biot-(S)-Glu5-Bz-1 and Sav S112C yielded 33% (R) and 12% conversion for N-
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AcPhe, whereas 72% (R) and 96% conversion for N-AcAla (Table 6, entry 17 and 
23). This trend has been observed in the catalytic results of the first generation of 
artificial hydrogenases (using achiral spacers) 165. 
Interestingly, some catalytic results show that incorporation of ligands in avidin 
competes with the results obtained with WT sav, which in general performs best 
(Table 6, entry 14 vs. 16 and entry 15 vs. 17). 
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Figure 12. Enantioselectivity histogram as a function of chemical component in the presence of twenty 
streptavidin isoforms (catalytic results combining mutation in position 112, 114-116 and double point 
mutations are included). 
 
 Combining Biot–(R)-Pro–1 with Sav mutants bearing aromatic residues at 
position S112X (S112W and S112Y) affords the most (S)-selective artificial 
hydrogenases (up to 95% ee for both substrates, Table 6, entries 3-4).  
 The hybrid catalysts derived from Biot–(S)-Phe–1 afford both (R)- and (S)-
reduction products. For example, [Rh(COD)Biot–(S)-Phe–1]+ ⊂ Sav S112M and 
[Rh(COD)Biot–(S)-Phe–1]+ ⊂ Sav S112H yield quantitatively N-AcPhe in 88% ee 
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(R) and 79% ee (S) respectively (Scheme 37, and Table 6, entries 10-11). For a single 
mutation, this represents a difference in transition state free energy ΔΔG‡ > 2.6 
kcal·mol-1 at room temperature. Irrespective of the absolute configuration of the 
phenylalanine spacer, hybrid catalysts derived from S112F, S112L, S112M, S112W 
and S112Y streptavidin mutants afford preferentially the same enantiomer.  
 Both [Rh(COD)Biot–(R)-Phe–1]+ ⊂ Sav S112M and [Rh(COD)Biot–(S)-Phe–1]+ 
⊂ Sav S112M yield quantitatively (R)-N-AcAla in 86% ee and 73% ee respectively 
(Table 6, entries 7 and 11). We speculate that the presence of a bulky residue at 
position S112 outrules the preference imposed by the enantiopure Phe-spacer. This 
may be achieved either by inverting the preferred enantioenriched ligand 
conformation or by forcing the prochiral substrate to present its si-face to the 
biotinylated catalyst. 
 
Scheme 37. Reduction of α-acetamidocinnamic acid using WT Sav as starting point, combined with 
Biot-(R)-Pro-1 affording 91% ee (S) that can be fine-tuned to 63 % ee (R) upon combination with 
Biot-(R)-Phe-1 (red diagram). Genetic optimization yielded high diversity ranging from 79% ee (S) to 
88% ee (R) using the same vector Biot-(S)-Phe-1 (black diagram). Inset: Fingerprint display of the 
results for the chemogenetic optimization. 
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 Both substrates afford comparable enantioselectivities. However, slightly better 
conversions are generally obtained for the smaller product N-AcAla. Significant 
substrate discriminations are found for catalysts derived from Biot–(R)-Pro–1. For 
example, [Rh(COD)Biot–(R)-Pro–1]+ ⊂ Sav S112K affords quantitatively (S)-N-
AcAla (88% ee), while the conversion for the larger (S)-N-AcPhe remains modest 
(36% conversion, 84% ee, Table 6, entry 2). 
 Regardless the configuration of enantiopure amino acid, the introduction of 
glutamic acid as spacer afforded substrate specific artificial hydrogenases (Table 6, 
entries 17, 21-23), compared to the others spacers (phenylalanine, proline, and 
pipecolinic acid).  
 Combining Biot–(R)-Pro–1 with WT Avi affords, for the first time, good levels 
of enantioselection (89% ee for N-AcPhe quantitative conversion, Table 6 entry 1). 
This may be of interest for future developments as WT Avi is significantly cheaper 
than WT Sav. 
Table 6. Numerical summary of selected results of the catalytic experiments using second-generation 
artificial hydrogenases.  
Entry Ligand Protein ee[a] 
N-AcPhe 
Conv. 
N-AcPhe 
ee[a] 
N-AcAla 
Conv. 
N-AcAla 
1[c] Biot–(R)-Pro–1 WT Avi -89 quant.[b] -87 quant.[b] 
2 Biot–(R)-Pro–1 S112K -84 36 -88 quant.[b] 
3 Biot–(R)-Pro–1 S112W -95 quant.[b] -95 quant.[b] 
4 Biot–(R)-Pro–1 S112Y -93 97 -92 quant.[b] 
5 Biot–(R)-Phe–1 S112I 74 80 84 quant.[b] 
6 Biot–(R)-Phe–1 S112L 74 88 83 quant.[b] 
7 Biot–(R)-Phe–1 S112M 75 94 86 quant.[b] 
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8 Biot–(R)-Phe–1 S112Q 76 82 81 quant.[b] 
9 Biot–(R)-Phe–1 S112R 82 75 84 quant.[b] 
10 Biot–(S)-Phe–1 S112H -78 65 -87 quant.[b] 
11 Biot–(S)-Phe–1 S112M 87 quant.[b] 73 quant.[b] 
12 Biot–(R)-Pip–1  -4 80 -8 quant.[b] 
13 Biot–(R)-Glu5-Bz–1  -9 28 -7 quant.[b] 
14 Biot–(R)-Pip–1 WT Avi -85 96 -68 quant.[b] 
15 Biot–(R)-Glu5-Bz–1 WT Avi -60 92 -38 quant.[b] 
16 Biot–(R)-Pip–1 WT Sav -82 69 -81 quant.[b] 
17 Biot–(R)-Glu5-Bz–1 WT Sav -30 15 -11 86 
18 Biot–(R)-Pip–1 S112W -90 78 -82 quant.[b] 
19 Biot–(R)-Pip–1 S112E -86 69 -87 quant.[b] 
20 Biot–(S)-Pip–1 S112F 11 69 64 quant.[b] 
21 Biot–(R)-Glu5-Bz–1 S112W -70 22 -78 78 
22 Biot–(S)-Glu5-Bz–1 S112M 41 51 79 quant.[b] 
23 Biot–(S)-Glu5-Bz–1 S112C 33 12 72 96 
24 Biot–(S)-Glu5-Bz–1 S112L -28 79 41 quant.[b] 
[a]ee in %, positive ee values in favor of the (R)-enantiomer, negative ee values in favor of the (S)-
enantiomer; [b]quantitative; all listed experiments were performed at least in duplicate (see Supporting 
Information); [c]according reference 168; N-AcPhe = N-acetamidophenylalanine, N-AcAla = N-
acetamidoalanine. 
 
 
3.2.2. Single point mutation (at position 114, 115 and 116) & double point 
mutation 
To elucidate the role of the proximal amino acid residues in the binding pocket 
of (strept)avidin, we performed a docking study to determine the closest amino acid 
residues around metal center responsible to perturb the interaction of the metal center 
with binding pocket environment. The docking studies suggest that position 114, 115, 
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and 116, which is situated in loop 7 and 8 of streptavidin could be potentially 
interesting to be modified. For this purpose, in position 114, we have introduced 
glycine instead of threonine, in position 115, we have replaced threonine by alanine 
and in position 116, alanine replaced glutamic acid. The position 114, 115 and 116 in 
loop 7 and 8 of monomeric streptavidin is depicted in Scheme 38. 
 
Scheme 38. Structure of monomeric streptavidin with highlighted position of mutation in position 114 
(green), 115 (yellow) and 116 (red). 
 
3.2.2.1. Combination with achiral spacer 
The first attempt was to attach the first generation of artificial hydrogenases 
within the modified host protein. Two ligand scaffolds, Biot-1 and Biot-2 were used 
in this preliminary test. A cocktail mixture of α-acetamidoacrylic acid and α-
acetamidocinnamic acid was used. The detailed operating conditions, together with 
the structure of the ligands used, are depicted in Scheme 39. 
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Scheme 39. Achiral biotinylated ligands used in this study and standard operating conditions for the 
hydrogenation of a cocktail mixture containing α-acetamidoacrylic acid and α-acetamidocinnamic acid 
(50 equivalents of each with respect to the biotinylated ligand). 
 
The results of the catalytic run were collected and compiled in the fingerprint 
presentation as depicted in Scheme 40. 
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Scheme 40. Fingerprint display of the results of the chemogenetic optimization of α-acetamidoacrylic 
acid (top triangle) and α-acetamidocinnamic acid (bottom triangle) using achiral spacer ligands and 
single point mutation in position 114-116 and dual point mutations. 
 
Scheme 40 suggests that ligand scaffold 1 outperforms ligand scaffold 2. In 
principle, the smaller substrate, α-acetamidoacrylic acid was hydrogenated with better 
performance compared to the bulky one, α-acetamidoncinammic acid. It is known 
that in the enantioselective homogeneous hydrogenation of enamide with cationic 
rhodium complexes, that increasing substitution in alkene part drive to a direct and 
negative effect on the performance of the catalyst. Although similarity of the 
substrates displaying a real steric difference, due to the presence of the phenyl ring on 
the prochiral C=C double bond of α-acetamidocinammic acid. Steric interactions 
within the binding pocket of (strept)avidin are therefore unavoidable, thus the smaller 
substrate may have better access to the cavity of the binding pocket of (strept)avidin 
than more bulky substrate α-acetamidocinnamic acid. 
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 Mutation of amino acids in two different positions displayed an advantage to 
finely tune the reduction product of hydrogenation. For example, using Biot-31-2 as 
ligand, in combination with S112G-N118T afforded 54% (S) reduction product, 
whereas 59% (R) reduction product was obtained upon combination with V47G-
S112G (Table 7, entry 4 and 8). It is noteworthy that for some combinations, double 
points mutations does not seem to influence the inversion of reduction product (Table 
7, entries 2-3, 6-7). 
 In the case of single point mutation in position 114, 115 and 116, with 
exception in combination with Biot-35-2 and Biot-31-1, all catalytic result yielded 
comparable values of enantioselectivity (Table 7, entries 10, 15, 20 and 12, 17, 22). 
However, a slightly lower enantioselectivity was observed when combining with 
mutation in position 116 (or 115), in comparison with mutation in position in position 
114 (Table 7, entries 9, 14, 19 and 11, 16, 21). 
3.2.2.2. Combination with chiral spacer 
Having identified the outcome of interaction of the double point mutation and 
single point mutation at position 114, 115, and 116 with the achiral-spacer ligands, 
the next attempt was to combine these mutants with the chiral-spacer ligands in 
catalytic experiments.  The results were collected and compiled in the fingerprint 
presentation and some interesting results were outlined in Table 7. 
Based on Scheme 35, it is clear that enantioselectivity is determined by-and-
large by spacer between biotin moiety and diphosphine anchor. Again, Biot-(R)-Pro-
1, Biot-(S)-Phe-1 and Biot-(R)-Pip-1 favor the formation of (S)-reduction products, 
whereas Biot-(S)-Pro-1, Biot-(R)-Phe-1 and Biot-(S)-Glu5-Bz-1 afforded 
preferentially (R)-reduction products. 
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Single point mutation in position 114, 115 and 116 yielded similar behavior 
upon incorporation with biotinylated complexes, this observation is valid especially in 
combination with chiral-spacer ligands (Scheme 35 and Table 7, entries 24-26). 
Except for a lower conversion, the mutants T114G, T115A, and E116A react 
indiscriminately to afford the same enantioselectivity level. 
Table 7. Numerical summary of selected results of the catalytic experiments: chemogenetic 
optimization in position 114, 115, and 116, and dual point mutations. 
Entry Ligand Protein ee[a] 
N-AcPhe 
Conv. 
N-AcPhe 
ee[a] 
N-AcAla 
Conv. 
N-AcAla 
1 Biot–1 S112G-N118T 86 93 94 quant.[b] 
2 Biot–32–1 S112G-N118T -53 97 -42 quant.[b] 
3 Biot–4meta–1 S112G-N118T -54 49 -14 quant.[b] 
4 Biot–31–2 S112G-N118T -7 10 -54 quant.[b] 
5 Biot–1 V47G-S112G 15 84 7 quant.[b] 
6 Biot–32–1 V47G-S112G -52 92 -44 quant.[b] 
7 Biot–4meta–1 V47G-S112G -30 8 -33 quant.[b] 
8 Biot–31–2 V47G-S112G 45 28 59 quant.[b] 
9 Biot–1 T114G 93 67 94 quant.[b] 
10 Biot–31–1 T114G -56 4 -52 77 
11 Biot–4meta–1 T114G -79 88 -59 quant.[b] 
12 Biot–35–2 T114G -59 96 -24 quant.[b] 
13 Biot–4ortho–2 T114G -22 20 -8 quant.[b] 
14 Biot–1 T115A 91 quant.[b] 94 quant.[b] 
15 Biot–31–1 T115A -27 5 -22 80 
16 Biot–4meta–1 T115A -62 70 -55 quant.[b] 
17 Biot–35–2 T115A -8 56 4 quant.[b] 
18 Biot–4ortho–2 T115A -29 10 -53 quant.[b] 
19 Biot–1 E116A 91 29 93 quant.[b] 
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20 Biot–31–1 E116A -40 3 -26 39 
21 Biot–4meta–1 E116A -56 26 -52 quant.[b] 
22 Biot–35–2 E116A 0 7 -2 quant.[b] 
23 Biot–4ortho–2 E116A -24 5 -53 quant.[b] 
24 Biot-(R)-Pro-1 T114G -93 79 -94 quant.[b] 
25 Biot-(R)-Pro-1 T115A -93 68 -89 quant.[b] 
26 Biot-(R)-Pro-1 E116A -92 32 -86 87 
27 Biot-(S)-Pip-1 V47G-S112G -47 78 -60 quant. [b] 
[a]ee in %, positive ee values in favor of the (R)-enantiomer, negative ee values in favor of the (S)-
enantiomer; [b]quantitative; N-AcPhe = N-acetamidophenylalanine, N-AcAla = N-acetamidoalanine. 
 
In summary and in comparison with previous studies relying on achiral 
spacers, the introduction of enantiopure spacers yields more (S)-selective artificial 
metalloenzymes (best result for the first generation 88% vs. 95% with second 
generation). In addition, the genetic optimization by saturation mutagenesis at 
position S112X Sav generates more diversity than previously observed with achiral 
spacers 165.  
3.3. Substrate scope 
In our attempt to broaden the substrate scope of artificial hydrogenases, the 
esters of protected amino acid substrates were used.  The structure of these substrates 
is depicted in Scheme 41 and the preliminary results of the enantioselective 
hydrogenations are compiled in Table 8. 
CO2Me
NHAc
CO2Me
NHAcPh
MAA MAC  
Scheme 41. Structure of MAA (methyl acetamidoacrylate) and MAC (methyl acetamidocinnamate). 
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Table 8. Numerical summary of selected results of the catalytic experiments using amino acid esters 
with the same conditions as catalytic experiments using acid as substrate.  
Entry Ligand Protein Substrate Conv. ee[a] 
1 Biot–1 WT Sav MAA 68 61 
2 Biot–1 WT Sav MAC 2 17 
3 Biot–(R)-Pro–1 WT Sav MAA 76 -17 
4 Biot–(R)-Pro–1 WT Sav MAC 10 -3 
5 Biot–(R)-Pro–1 S112A MAA 78 -22 
6 Biot–(R)-Pro–1 S112E MAA 28 -34 
7 Biot–(R)-Pro–1 S112H MAA 63 -20 
8 Biot–(R)-Pro–1 S112I MAA 88 -19 
9 Biot–(R)-Pro–1 S112K MAA 65 -26 
10 Biot–(R)-Pro–1 S112M MAA 85 -28 
11 Biot–(R)-Pro–1 S112W MAA 85 -28 
12 Biot–(R)-Pro–1 S112W MAC 85 -28 
13 Biot–(S)-Phe–1 WT Sav MAA 88 -39 
14 Biot–(S)-Phe–1 WT Sav MAC 13 -14 
15 Biot–(S)-Phe–1 S112M MAA quant.[b] 8 
16 Biot–(S)-Phe–1 S112M MAC 22 2 
17 Biot–(S)-Phe–1 S112H MAA 88 -55 
18 Biot–(S)-Phe–1 S112H MAC 9 -31 
[a]ee in %, positive ee values in favor of the (R)-enantiomer, negative ee values in favor of the (S)-
enantiomer; [b]quantitative; MAA =  methyl acetamidoacrylate; MAC = methyl acetamidocinnamate. 
 
As can be appreciated from Table 8, the artificial hydrogenases yielded 
modest enantioselectivity (up to 61% (R) and 55% (S)) and low to moderate activity 
for the enantioselective hydrogenation of the esters compared to the corresponding 
acids. Recently, Reetz 169 reported asymmetric hydrogenation of methyl 
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acetamidoacrylate with [Rh(COD)(Biot-1)]+ ⊂ WT Sav affording ee 23% (R). It is 
noteworthy that Reetz used slightly different condition (pH, substrate concentration, 
and so forth) for the reaction. In addition, Reetz focused his studies exclusively on the 
genetic optimization  (saturation mutagenesis), the best ees obtained are 65% in favor 
of (R) in combination of Biot-1 with N49V and 7% in favor of (S) in combination of 
Biot-1 with N49H-L124F. 
Another type of substrate i.e. ketopantolactone was tested for the first time for 
the reduction of C=O bond (shown in Scheme 42). For this purpose, the most 
versatile (R)- and (S)-selective artificial hydrogenases were selected and tested: 
[Rh(COD)(Biot-1)]+ ⊂ WT Sav  (highly (R)-selective) and [Rh(COD)(Biot-(R)-Pro-
1)]+ ⊂ S112W (highly (S)-selective). The preliminary study suggested that for the 
reduction of C=O bond, high pressure is required (P > 20 bar). 
 
O
O
O O
OH
O
H
O
H
O
HO
H2 (30 bar), H2O:MeOH=10:1
rt, 15 h
1.0 mol % ligand
0.9 mol % [RhCOD)2]BF4
0.33 mol % streptavidin
+
ketopantolactone (R)-(-)- (S)-(-)-
pantolactone  
Scheme 42. Asymmetric hydrogenation of ketopantolactone using artificial hydrogenases generated 
from biotin-avidin technology. 
 
The experimental results are collected in Table 9. From this preliminary 
study, it is interesting to note that artificial hydrogenases were little active and 
selective for the reduction of C=O bond. As control experiments, [Rh(COD)(Biot-1)]+ 
in WT Sav and [Rh(COD)(Biot-(R)-Pro-1)]+ in S112W were charged with standard 
substrates (α-acetamidoacrylic acid and α-acetamidocinnamic acid) and standard 
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conditions (S/C = 100, catalyst/protein = 3, Rh-complex dissolved in DMSO, except 
with P = 30 bar instead of 5 bar). The results revealed that Biot-1 in WT Sav afforded 
a racemic mixture, whereas [Rh(COD)(Biot-(R)-Pro-1)]+ in S112W was still highly 
selective, albeit with a slight decrease in enantioselectivity (total conversion and 86% 
ee (S) vs. total conversion and 95% (S) with P = 5 bar). This is the first time that the 
artificial hydrogenases generated from biotin-avidin interactions showed the high 
selectivity and activity under high-pressure dihydrogen 152.  
Table 9. Numerical catalytic results of enantioselective hydrogenation of ketopentalactone 
Entry Ligand Protein Conv. ee[a] 
1 Biot-1 WT Sav 9 -2 
2 Biot–(R)-Pro–1 WT Sav 18 -37 
3 Biot–(R)-Pro–1 S112W 31 -61 
[a]ee in %, positive ee values in favor of the (R)-enantiomer, negative ee values in favor of the (S)-
enantiomer. 
3.4. Organic solvent tolerance 
Having identified both (R)- and (S)-selective (ee > 90%) artificial 
hydrogenases, we proceeded to test these artificial hydrogenases in the presence of 
large amounts of organic co-solvents. For this purpose, dimethylsulfoxide (DMSO, 
miscible with water) and ethylacetate (EtOAc, non-miscible with water) were 
selected. The results for the screening in the presence of the most selective catalyst ⊂ 
protein combinations are summarized in Table 10. 
As can be appreciated from these data, the catalyst derived from Biot–1 does 
not tolerate large amounts of either DMSO or EtOAc (Table 10, entries 1-2). 
Introduction of an enantiopure spacer confers significant organic-solvent tolerance in 
the presence of streptavidin and its mutants. Both (S)- and (R)-selective catalysts 
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[Rh(COD)Biot–(R)-Pro–1]+ ⊂ Sav S112W and [Rh(COD)Biot–(S)-Phe–1]+ ⊂ Sav 
S112M perform well in the presence of either 45% DMSO or EtOAc (maximal ee 
erosion 12%, Table 10, entries 12-13 and 15-16).  
In contrast to streptavidin isoforms as host proteins, avidin-based artificial 
metalloenzymes perform poorly in the presence 45% DMSO (Table 10, entries 4-5 
and 8-9). In the presence of either 27% DMSO or EtOAc, the erosion observed with 
[Rh(COD)Biot–(R)-Pro–1]+ ⊂ WT-Avi is minimal (Table 10, entries 8 and 10). One 
of the main limitations of enantioselective catalysis performed in aqueous media is 
the very limited solubility of many substrates. The organic solvent tolerance should 
thus contribute to broaden the substrate scope of these artificial metalloenzymes. 
The composition of solutions in the reaction mixture is illustrated in Scheme 43 for 
both monophasic and biphasic systems. 
 
Scheme 43. Composition of solutions for monophasic (A) and biphasic (B) conditions in asymmetric 
hydrogenation. 
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3.5. Immobilization of artificial hydrogenases 
In the past 152, Dr. J. Collot had shown that an artificial metalloenzyme’s 
selectivity is little affected upon varying the ratio of [Rh(COD)(Biot–1)]+ versus WT 
Sav between one and four, suggesting that the occupancy of one binding site does not 
significantly affect neighboring sites. As streptavidin is a homo-tetrameric protein, we 
speculated that it may be possible to exploit one binding site to immobilize the 
artificial metalloenzyme, leaving three sites for the incorporation of a biotinylated 
catalyst. A schematic flowchart of the preparation of immobilized catalysts is shown 
in Scheme 44. While Scheme 45 illustrates the immobilization of Rh-complex using 
biotin-sepharose. 
Biotin-sepharose
in solution
Incubation of protein
with biotin-sepharose
Protein immobilized 
on biotin-sepharose
Incubation of immobilized
protein with Rh-complex
Immobilized catalyst
ready to use
Washing
Washing Degassing
Washing
 
Scheme 44. Flowchart of preparation immobilized artificial hydrogenases using biotin-sepharose as 
solid support. 
 
For this purpose, one equivalent of commercially available biotin-sepharose was 
added to tetrameric (strept)avidin prior to the addition of an excess biotinylated 
catalyst precursor (Scheme 45). 
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Scheme 45. Immobilization of a Rh-biotinylated complex using biotin-sepharose. One equivalent of 
biotin-sepharose binds a biotin-binding site of the host protein leaving up to three binding pockets for 
anchoring of the biotinylated pre-catalysts. 
 
After decanting the immobilized catalyst precursors, thus removing the excess 
biotinylated rhodium and the unbound protein present in solution, these were tested 
using the standard reaction conditions. Selected results are collected in Table 10. As 
can be appreciated, the immobilized artificial metalloenzymes are most often nearly 
as selective as their homogeneous counterparts. However, the activity decreases, 
especially for the larger α-acetamidocinnamic acid substrate. The most versatile 
immobilized hybrid catalyst is [Rh(COD)Biot–(R)-Pro–1]+ ⊂ Sav S112W which is as 
active and as selective as its homogeneous counterpart (compare Table 5 entry 3 and 
Table 10 entry 14). 
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Table 10. Numerical summary of selected results of the catalytic experiments performed in the 
presence of organic solvents or with immobilized artificial metalloenzymes.  
Entry Ligand Protein Organic 
solvent 
ee[a] 
N-AcPhe 
Conv. 
N-AcPhe 
ee[a] 
N-AcAla 
Conv. 
N-AcAla 
1[b] Biot–1 WT Sav 45 % 
DMSO 24 9 16 71 
2[b] Biot–1 WT Sav EtOAc 31 5 30 56 
3 Biot–1 WT Sav Immob.[d] 93 78 83 quant.[c] 
4 Biot–(R)-Pro–1 WT Sav 27 % 
DMSO -91 100 -87 quant.[c] 
5[b] Biot–(R)-Pro–1 WT Sav 45 % 
DMSO -86 94 -87 quant.[c] 
6[b] Biot–(R)-Pro–1 WT Sav EtOAc -87 85 -83 90 
7 Biot–(R)-Pro–1 WT Sav Immob.[d] -89 36 -76 76 
8 Biot–(R)-Pro–1 WT Avi 27 % 
DMSO -82 94 -86 quant.[c] 
9 Biot–(R)-Pro–1 WT Avi 45 % 
DMSO -15 34 -37 quant.[c] 
10 Biot–(R)-Pro–1 WT Avi EtOAc -89 77 -87 quant.[c] 
11 Biot–(R)-Pro–1 WT Avi Immob.[d] -80 32 -76 quant.[c] 
12 Biot–(R)-Pro–1 S112W  45 % 
DMSO -88 56 -85 quant.[c] 
13 Biot–(R)-Pro–1 S112W  EtOAc -94 86 -94 quant.[c] 
14 Biot–(R)-Pro–1 S112W  Immob.[d] -94 89 -92 quant.[c] 
15 Biot–(S)-Phe–1 S112M Sav 45 % 
DMSO 75 68 69 quant.[c] 
16 Biot–(S)-Phe–1 S112M Sav EtOAc 81 78 64 quant.[c] 
17 Biot–(S)-Phe–1 S112M Sav Immob.[d] 81 50 33 quant.[c] 
18 Biot–(R)-Pro–1 T114G Immob.[d] -94 82 -89 quant.[c] 
19 Biot–1 T114G Immob.[d] 94 68 -88 quant.[c] 
20 Biot–32–2 S112Q Immob.[d] 89 79 72 quant.[c] 
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[a]ee in %, positive ee values in favor of the (R)-enantiomer, negative ee values in favor of the (S)-
enantiomer; [b]according reference 22; [c]quantitative; [d]Immobilized; N-AcPhe = N-
acetamidophenylalanine, N-AcAla = N-acetamidoalanine. 
 
As preliminary study to recover and re-use the immobilized catalysts, we have 
chosen the most versatile catalyst, [Rh(COD)Biot–(R)-Pro–1]+ ⊂ Sav S112W 
system. By removing the reaction mixture at the end of reaction (after ca. 15 hours), 
the substrate solution with the same quantity as the first cycle (S/C = 100) was added 
into the immobilized catalyst to run the 2nd cycle of catalyst. We observed that the 
immobilized catalyst could be recovered and reused up to 1 additional catalytic cycle 
without decreasing significantly the enantioselectivity. For the combination of  
[Rh(COD)Biot–(R)-Pro–1]+ ⊂ Sav S112W as catalyst, and α-acetamidocinnamic 
acid as substrate resulted: 94% (S) and quantitative conversion for the 1st cycle, then 
for the 2nd cycle 94% (S) and 81% conversion, 3rd cycle >30% (S) and >25% 
conversion. 
  
To assess the tolerance towards organic solvents of the immobilized catalysts, we 
attempted to add the ratio of the organic solvent in solution and to run the reaction 
using the immobilized catalysts. The results are collected in Table 10. 
Table 11. Numerical summary of selected results of the catalytic experiments using immobilized 
catayst (with [Rh(COD)Biot–(R)-Pro–1]+) in the presence of organic solvents.  
Entry condition Protein ee[a] 
N-AcPhe 
Conv. 
N-AcPhe 
ee[a] 
N-AcAla 
Conv. 
N-AcAla 
1 10% DMSO WT Avi -80 32 -76 quant.[b] 
2 45% DMSO WT Avi -40 12 -31 58 
3 EtOAc biphasic WT Avi -77 10 -80 64 
4 10% DMSO WT Sav -89 36 -76 76 
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5 45% DMSO WT Sav -50 14 -71 70 
6 EtOAc biphasic WT Sav -70 3 -49 5 
7 10% DMSO S112W -94 89 -92 quant.[b] 
8 45% DMSO S112W -91 35 -91 96 
9 EtOAc biphasic S112W -93 83 -94 quant.[b] 
10 10% DMSO T114G -94 82 -89 quant.[b] 
11 45% DMSO T114G -56 11 -76 84 
12 EtOAc biphasic T114G -65 4 -76 13 
[a]ee in %, positive ee values in favor of the (R)-enantiomer, negative ee values in favor of the (S)-
enantiomer; [b]quantitative; N-AcPhe = N-acetamidophenylalanine, N-AcAla = N-acetamidoalanine. 
 
Incorporation of [Rh(COD)Biot–(R)-Pro–1]+ in S112W afforded a highly resistant 
and tolerant artificial hydrogenase towards organic solvent. In addition, its activity 
and selectivity remains stable upon immobilization with biotin-sepharose. This 
feature is promising for future studies. 
 
3.6. Michaelis-Menten kinetics: determination of individual reaction rates  
In preliminary report, our group has demonstrated that the host protein does 
not only responsible for inducing enantioselectivity but also for increasing the activity 
of the catalyst. This phenomenon is called “protein accelerated catalyst” 153. With 
this spirit, we set out to quantify this phenomenon by determining the individual 
reaction rates.  
For solubility reasons, only α-acetamidoacrylic acid was chosen as substrate. 
Michaelis-Menten model appeared to be an ideal model for this system. The kinetic 
data were collected at given time, by performing independent reactions with different 
initial concentration of substrate. The typical data are collected and compiled in Table 
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12 (the data set of the 3 other systems can be found in the supporting information in 
Chapter 5). 
Table 12. Experimental kinetic data of [Rh(COD)(Biot-1)]+ ⊂ WT Sav. 
Concentration of 
substrate (mM) 
Time  
(min) 
Conv. (%) 
by GC 
ν 
(mM.min-1) 
0 0 0 0 
2.83 2 8 0.113 
3.96 3 11 0.145 
5.09 3 9 0.153 
5.65 5 15 0.170 
11.30 5 9 0.203 
16.95 10 12 0.203 
28.25 10 8 0.226 
33.90 10 7 0.237 
 
It is noteworthy that only the rate of the reaction in the pre-steady state is 
taken into account in calculation. In order to obtain the kinetics parameters, an initial 
value, maximum rate and rate constant, are inserted into the Michaelis-Menten 
equations (equation 1 and 2) to allow non-linear least-squares minimization 
! 
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  (2) 
The initial rate was obtained by dividing the conversion (by GC) with time. 
The ee of the reduction products is constant during the course of the reaction. 
Moreover, no induction period or catalyst inhibition were observed during the course 
of the reaction. The comparison of calculated and measured values for the four 
observed systems is depicted in Figure 13 as a Michaelis-Menten plot. 
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Figure 13. Michaelis-Menten plot for different systems:  [Rh(COD)Biot–(R)-Pro–1]+ ⊂ WT Sav  
[Rh(COD)Biot–(R)-Pro–1]+ ⊂ WT Avi  [Rh(COD)(Biot–1))]+ ⊂ WT Sav   [Rh(COD)(Biot–1)]+ 
free protein.  
 
The calculated values (KM and Vmax) obtained from the iteration procedures are 
compiled in Table 13. 
 
Table 13. Kinetics parameters derived from Michaelis-Menten equations. 
entry Ligand Protein 
Vmax 
(mM.min-1) 
kcat 
(min-1) 
KM 
(mM) 
kcat/KM 
(min.mM-1) 
1 Biot-1 - 0.173 3.06 7.38 0.42 
2 Biot-1 WT Sav 0.254 4.49 3.18 1.41 
3 Biot-(R)-Pro-1 WT Sav 0.695 12.30 4.36 2.82 
4 Biot-(R)-Pro-1 WT Avi 0.634 11.23 4.80 2.34 
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From these observations, interesting features are: 
 All catalytic systems follow the Michaelis-Menten model. This behaviour is 
similar to natural enzymes. 
 In comparison to protein-free catalyst, all artifical hydrogenases display higher 
affinity (up to two fold) and higher rate constants (up to three fold). A plausible 
reason for this may be the presence of a hydrophobic pocket providing a favourable 
environment for the mass transfer of dihydrogen to access the active site of the 
artificial metalloenzymes 
 Both host proteins streptavidin and avidin, display the similar kinetics behaviour.  
 The presence of DMSO contributes to increase the reaction rates. Some previous 
studies revealed that the solubility of dihydrogen in organic solvent is significantly 
higher than in aqueous counterpart 170, thus contributing to the mass transfer of the 
dihydrogen thus increasing the reaction rate.  
To compare the values of the kinetics parameters with different available 
methods, we have performed evaluation through linearization graphical methods, such 
as Eaddie-Hofstee 171-173 and Lineweaver-Burk models 172, 174. 
A linearization method is commonly used for a graphical representation of the 
kinetic data. This was performed either by Lineweaver-Burk plot or Eadie-Hofstee 
plot. These two methods are used routinely in enzymatic catalysis, although the latter 
is considered to be better and more accurate than the Lineweaver-Burk method. The 
Lineweaver-Burk or double reciprocal is very useful to analyze data graphically and 
to detect deviations from an ideal behaviour. By plotting 1/ν vs. 1/[S] curve, one can 
extract the maximum initial rate, Vmax, from the inverse of constant of the linear 
equation (3). The slope of this curve corresponds to ratio KM/Vmax. As Vmax is known, 
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KM can be extracted. Re-arranging equation (1), we obtain equation (3) which relates 
1/ν and 1/[S]. 
 
! 
1
"
=
K
M
V
max
1
S[ ]
+
1
V
max
 (3) 
 
Table 14. Initial reaction rates obtained from kinetic experiments for [Rh(COD)(Biot-1)]+ ⊂ WT Sav 
and parameters values to construct Lineweaver-Burk and Eadie-Hofstee plots. 
[S]  
(mM) 
Time 
(min) 
Conv. 
(%) 
ν  
(mM.min-1) 
1/[S] 
(mM-1) 
1/ν 
(mM-1.min) 
ν/[S] 
(min-1) 
0 0 0 0 - - - 
2.825 2 8 0.113 0.354 8.85 0.040 
3.955 3 11 0.145 0.252 6.89 0.037 
5.085 3 9 0.153 0.197 6.55 0.030 
5.65 5 15 0.169 0.177 5.90 0.030 
11.3 5 9 0.203 0.089 4.91 0.018 
16.95 10 12 0.203 0.059 4.91 0.012 
28.25 10 8 0.226 0.035 4.24 0.008 
33.9 10 7 0.237 0.029 4.21 0.007 
 
The graphical representation of the Lineweaver-Burk plot is depicted in Figure 14. 
Kinetic parameters obtained from this linearization are Vmax = 0.259 mM.min-1 and 
KM = 3.43 mM. 
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Figure 14. Lineweaver-Burk plot for determination of kinetic parameters for [Rh(COD)(Biot-1)]+ ⊂ 
WT Sav. The fitted equation is highlighted in red with R2 = 0.977.  
 
Another graphical method, the Eadie-Hofstee plot, relating initial rate ν vs. 
ν/[S], with equation 
! 
" = #K
M
"
S[ ]
+V
max
 (4) affords the following kinetic values: KM = 
3.22 mM and Vmax = 0.254 mM/min and the plot of this equation is depicted in Figure 
15.  From this example, it is obvious that with the Eadie-Hofstee method, the kinetic 
parameters can be extracted directly from equation (4). Furthermore, it is known that 
this method has a clear advantage in robustness against error-prone data than the 
Lineweaver-Burk plot. Particularly, it yields equal weight to data points in any range 
of substrate concentration or reaction rate, thus the typical measure goodness of fit, 
correlation coefficient R2, is no longer applicable. 
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Figure 15. Eadie-Hofstee plot for determination of kinetic parameters for [Rh(COD)(Biot-1)]+ ⊂ WT 
Sav. 
 
As stated above, the kinetics parameters obtained from these two linearization 
methods are slightly different. The Eadie-Hofstee linearization yields quite similar 
kinetics parameters compared to the Michaelis-Menten model. 
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4. SUMMARY & OUTLOOK 
4.1. Summary 
This work describes the thermodynamic, kinetic and enantioselectivity 
considerations of artificial metalloenzymes based on the biotin-avidin technology. 
These studies focused on improving the performance of the first-generation artificial 
hydrogenases based on biotin-avidin technology.  
In chapter 2, a straightforward methodology using CD spectroscopy was used 
to determine the association constants of biotinylated coordination compounds 
[Ru(bpy)2(Biot-bpy)]2+ within (strept)avidin. It was demonstrated that bulky 
biotinylated coordination compounds can occupy four biotin binding sites of 
(strept)avidin. The binding affinity, however, is significantly reduced compared to 
native biotin  (ca. 5-7 orders magnitude lower: Ka biotin ⊂ streptavidin = 1013 M-1). 
Moreover, no significant chiral discrimination between the Δ− and Λ− diastreomers 
[Ru(bpy)2(Biot-bpy)]2+ could be observed upon binding to streptavidin. 
In chapter 3 we demonstrated that the biotin-avidin technology could be 
exploited to create artificial hydrogenases. Building upon previous work within the 
group, we showed that a second generation of artificial hydrogenases bearing 
enantiopure amino acid-spacers, affords both (R) and (S)-selective hydrogenases. The 
highest ee in favor of (S)-reduction product was obtained with [Rh(COD)Biot-(R)-
Pro-1)]+ ⊂ Sav S112W (95% ee (S) for both N-AcAla and N-AcPhe). In addition, 
combination of ligands bearing enantiopure spacers with isoforms of streptavidin 
provided significantly more diversity in term of genetic optimization. In some cases, 
it was shown that combination of avidin with chiral-spacer ligands outperformed 
streptavidin as a host. This may be interesting for the future use, as avidin is much 
cheaper than streptavidin. Another interesting feature of the second-generation 
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artificial hydrogenases is the organic solvent tolerance. This remarkable property was 
not observed in the first generation of artificial hydrogenases bearing achiral spacer-
ligands. A high-tolerance towards organic solvents is crucial in the design of 
metalloenzymes as most of the substrates are little soluble in water. 
In the present work, we also demonstrated that it is possible to immobilize the 
host protein with commercially available biotin-sepharose. It was found that, again 
combination [Rh(COD)Biot-(R)-Pro-1)]+ ⊂ Sav S112W emerged to catalyze nearly 
as efficiently as its homogeneous counterpart. Additionally, preliminary studies 
revealed that it is possible to recycle and reuse immobilized metalloenzymes. 
Determination of reaction rates using Michaelis-Menten kinetics are presented 
and discussed in Chapter 3. It was found that all catalytic systems follow a Michaelis-
Menten mechanism. An increase in reaction rate and in substrate-catalyst affinity was 
observed upon incorporation of metal-complexes within  (strept)avidin. This suggests 
that the host protein contributes to increase both the rate and the selectivity of the 
reaction. Reactions performed in the presence of DMSO proceed with higher rates. 
This may be due to a higher solubility of dihydrogen in this solvent compared to that 
in water. 
4.2. Outlook 
Introduction of a chiral spacer between biotin moiety and diphosphine 
afforded second-generation artificial hydrogenases. Although the new class of ligands 
showed a high tolerance towards organic solvents, it remains still difficult to broaden 
the substrate scope and to increase the TON/TOF of the reaction. As stated 
previously, one of the most important factors in the design of the catalyst is the ligand 
scaffold. It thus will be interesting to design another ligand scaffold to achieve a 
wider substrate scope. 
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The future research may be focused on the use of other type of metal for 
enantioselective hydrogenation (Ruthenium instead of Rhodium) as high-air 
sensitivity is one of the major problems using Rh-diphosphine as metal precursor.  
Biotin-sepharose allows the immobilization of the metalloenzymes and thus 
catalysis can be performed without using the purified protein. As protein purification 
is time-consuming, it is thus convenient to use directly the crude protein extract. 
The creation of metalloenzymes using the biotin-(strept)avidin technology and 
its spectacular results are just a beginning. We have successfully demonstrated that 
some important chemical transformations (hydrogenation, transfer hydrogenation, 
allylic alkylation) are conveniently catalyzed by artificial metalloenzymes using 
biotin-(strept)avidin technology. In the near future, it is obvious that more challenging 
chemical transformations can be performed using artificial metalloenzymes: 
hydroformylation, epoxidation, sulfoxidation, Suzuki coupling, and so forth. We have 
taken advantage the power of Nature to induce the selectivity (and activity) for 
chemical transformations. 
High-throughput screening and analysis can accelerate the procedure in 
finding the most versatile catalyst. The use of microdevices (e.g. microreactor) will 
allow a rapid identification and analysis of the outcome of the reaction; another 
advantage using the microdevices is that very small quantity of sample is required. A 
little more effort in optimization of the process will lead to industrial application of 
using artificial metalloenzymes.  
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5. SUPPORTING INFORMATION 
5.1. Materials, instrumentation and techniques.  
5.1.1. Abbreviation used 
BiotOC6F5   biotin-pentafluorophenol ester 
DMF    N,N’-dimethylformamide 
CD    circular dichroism 
CDMT    2-Chloro-4,6-dimethoxy-1,3,5-triazine 
CH2Cl2   dichloromethane (DCM) 
CH3CN   acetonitrile 
Conv.    conversion 
d    day(s) 
DMF    dimethylformamide 
DMSO    dimethylsulfoxide 
EtOAc    ethyl acetate 
ee    enantiomeric excess 
equiv    equivalent 
ESI    electron spray ionization 
EtOH    ethanol 
g, mg    gram, milligram 
GC     gas chromatography 
h    hour(s) 
HABA    2-(4’-hydroxyazoybenzene)benzoic acid 
H2O    water 
HCl    hydrochloric acid 
Hex    hexane 
HPLC    high performance liquid chromatography 
L, mL, mL   liter, milliliter, microliter 
M, mM   molar (mol·liter-1), millimolar (millimol·liter-1) 
MeOH    methanol 
MES    2-morpholinoethanesulfonic acid (pKa = 6.15) 
min    minute(s) 
 94 
MLCT    metal-to-ligand-charge transfer 
mol, mmol, mmol  mole, milimole, micromole 
MOPS    3-(N-morpholino)propanesulfonic acid (pKa = 7.2) 
MS    mass spectrometry 
NaOH    sodium hydroxide 
NH4PF6   amonium hexafluorophosphate 
NMR    nuclear magnetic resonance 
rt    room temperature 
s    second(s) 
Net3    triethylenamine 
TFA    trifluoroacetic acid 
TOF    turnover frequency (mol of product/mol  
of catalyst/time) 
TON     turnover number (mol of product/mol of catalyst) 
UV-Vis   ultraviolet-visible 
vs.    versus 
WT    wild-type (native) 
5.1.2. Reagents and solvents 
Reagents and solvents used in this work are listed in the Table 15. 
Table 15. Reagents and solvents used 
Substance Origin Quality grade and purity 
N-acetamidoacrylic acid Acros ≥ 99% 
N-acetamidocinnamic acid Fluka ≥ 99% 
Acetonitrile Acros ≥ 99.9% 
Ammonium 
Hexafluorophosphate 
Fluka ≥ 98% (gravimetric) 
Anisole Fluka ≥ 99% 
Avidin Belovo - 
(+)-biotin (D-biotin) Chanzou Huaren ≥ 99% 
Biotin-sepharose Affiland In NaN3 0.02% (w/v) 
2,2’-bipyridine Fluka Purum ≥ 98% (NT) 
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Boc-(D)Phe-OH Fluka ≥ 99% 
Boc-(L)Phe-OH Fluka ≥ 99% 
Boc-(D)Pro-OH Fluka ≥ 99% 
Boc-(L)Pro-OH Fluka ≥ 99% 
(R)-1-Boc-2-piperidine 
carboxylic acid 
Aldrich 98% 
(S)-1-Boc-2-piperidine 
carboxylic acid 
Aldrich 98% 
(R)-1-Boc-glutamic acid 
benzyl ester 
Senn  
(S)-1-Boc-glutamic acid 
benzyl ester 
Fluka 98 % 
(+)-O,O’-dibenzoyl-D-tartaric 
acid 
Fluka ≥ 99% 
(-)-O,O’-dibenzoyl-L-tartaric 
acid 
Fluka ≥ 99% 
N,N’-Diisopropylethylamine Fluka ≥ 98% 
N,N’-dimethylformamide Fluka ≥ 99.8% (GC) 
Dimethylformamide Fluka ≥ 99.5% (H2O ≤ 0.005 %) 
Dimethylsulfoxide Acros ≥ 99.9% 
Ethanol Merck p.a. ≥ 99.8% (GC) 
Ethylene glycol Fluka ≥ 99.5% (GC) 
Ethylenediamine Fluka ≥ 99% 
Hydrochloric acid Prochimie Solution 32% 
2-(4’-hydroxyazoybenzene) 
benzoic acid 
Sigma ≥ 98% (TLC) 
ketopantolactone DSM Nutrition ≥ 99% 
N-methylmorpholine Fluka ≥ 98 % 
2,3,4,5,6-pentafluorophenol Fluka ≥ 99 % (GC) 
Phosphate buffer  Merck Titrisol® pH 7.0 
Potassium hydroxide, pellets Fluka ≥ 99% 
Rh(COD)2BF4 Umicore  
Sephadex SP C-25  Pharmacia LKB  
Silica Brunschwig  32-63 60Å 
Sodium hydroxide, pellets Fluka Puriss. p.a ACS > 98% 
Streptavidin Own production  
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Triethylenamine Riedel-de-Haën ≥ 99% (GC) 
Trifluoroacetic acid Fluka ≥ 98% 
Trimethylsulfonium 
hydroxide 
Fluka 0.25 M in MeOH 
 
5.1.3. Preparative methods: column chromatography 
 Flash chromatography was carried out on silica gel 60, 32-63 mm. 
 SP Sephadex C-25 was used for ion exchange chromatography.  
 TLC (Thin Layer Chromatography) was performed on 0.2 mm silica gel 60 F254 
aluminium sheets from Merck. All biotinylated compounds were revealed as red spots 
with a solution of DACA (4-dimethylaminocinnamaldehyde) in methanol containing 
1% conc. H2SO4 175, 176. 
5.1.4. Analysis Instruments 
5.1.4.1. Absorption Spectrophotometry (UV/Vis) 
 The measurements were performed on a UVIKON 930 spectrophotometer 
from Kontron/BioTech. The sample solutions were measured in 1 cm quartz cells. 
The spectrophotometric data were imported and treated with MS excel. 
Indications in the spectroscopic data collection: λmax [nm] (εmax [M-1cm-1]). 
5.1.4.2. Circular Dichroism (CD) 
 CD spectra were recorded on a J-710 spectropolarimeter from JASCO, Tokyo 
(J). The sample solutions were measured in 1 cm quartz cells. The spectrophotometric 
data were imported and treated in SPECFIT/32 package. 
Indications in the spectroscopic data collection: λmax [nm] (Δεmax [M-1cm-1]). 
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5.1.4.2. Mass spectrometry (MS) 
 Mass spectra were recorded on a mass spectrometer LCQ from 
ThermoFinnigan, San José (USA), and on a mass spectrometer FTMS 4.7T BioAPEX 
II from Bruker, Billerica (USA) (at University of Fribourg). The ionization mode was 
for both electron spray ionization (ESI). Indications in the spectroscopic data 
collection: Mr of species (relative intensity, attribution). The relative intensity is given 
in % with respect to the strongest peak of the spectrum. 
5.1.4.3. Nuclear magnetic resonance (NMR) 
 Proton and carbon NMR spectra were recorded on spectrometer AMX-400 
(400.00 MHz for 1H, 100.58MHz for 13C, 376.31MHz for 19F, and 161.93MHz for 
31P) from Bruker, Billerica (USA). The samples were measured either in deuterated 
chloroform (99.8 % D) or deuterated dimethylsulfoxide (99.5 % D) from Cambridge 
Isotope Laboratories, Andover MA (USA). 
 Indication in the spectroscopic data collection: δ[ppm] relative to external 
standards TMS (1H, 13C), CFCl3 (19F) and H3PO4 (31P) (multiplicity (1H only, 
J[Hz](1H only), normalized integration values (1H only), attribution (1H and 13C 
only). The following abbreviations were used: s for singlet, d for doublet, dd for 
doublet of doublet, ddd for doublet of doublet of doublet, dt for doublet of triplet, t for 
triplet, q for quadruplet and m for multiplet. 
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5.2. Synthesis Protocols 
Synthesis and characterization of 5’-{2-[5-(2-Oxo-hexahydro-thieno[3,4-
d]imidazol-4-yl)pentanoylamino]-ethylcarbamoyl}-2,2’-bipyridinyl-5-carboxylic 
acid ethyl ester (Biot-bpy) 
 The biotinylated ethylenediamine and activated ester were synthesized 
according the Li and Somlai’s procedures 154, 155. Meanwhile the synthesis of Δ-
[Ru(bpy)2(py)2][(+)-O,O’-dibenzoyl-D-tartrate] · 12H2O  was achieved using von 
Zelewsky’s method 157, 158. The basic condition (pH = 8–9) is required to achieve a 
good solubility of tartaric acid 156. The experimental detail was described in previous 
report of our group 20. 
S
NHHN
O
HH H
N
O
N
N
O
OEt
O
N
H
Biot-bpy  
 
Synthesis of rac-[Ru(bpy)2(Biot-bpy)](PF6)2  and diastereopures 
 The synthesis and full characterization of rac-[Ru(bpy)2(Biot-bpy)](PF6)2 , Δ-
[Ru(bpy)2(Biot-bpy)](ClO4)2  and Λ-[Ru(bpy)2(Biot-bpy)](ClO4)2 were described in 
detail in previous report of our group 20. 
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Diphosphine ligands synthesis and characterization  
All ligands used herein were reported (synthesis and full characterization) in 
the supporting information of the preliminary communication 21, 164.  
 
Synthesis of biotinylated amidodiphosphine Biot-1 and Biot-2 
N
P
P
S
NHHN
H H
O
O
S
NHHN
H H
O
O
H
N
P
P
Biot-1 Biot-2  
Biot-1 or Biot-2 were prepared by the coupling of biotin N-Hydroxysuccinimide 
(BiotNHS) and H–1 HCl or H–2 according to the literature 21. 
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Synthesis of biotinylated amidodiphosphine ligands with 3n or 4q spacers 
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Biot-3n-1
Biot-4q-1
n = 1-5
q = ortho-, meta- and para-
Biot-4q-2
q = ortho-, meta- and para-
Biot-3n-2
n = 1-5
 
 
Biot-3n-1, Biot-4q-1, Biot-3n-2, Biot-4q-2 (n = 1-5, q = ortho-, meta- and para-) or 
Biot-2 were prepared according to the literature 21, by the coupling between 
biotinylated aminoacid (Biot-3n or Biot-4q (n = 1-5, q = ortho-, meta- and para-)) and 
diphosphino-amine (H–1 HCl or H–2).  
 
Synthesis of second generation of aminodiphosphine with chiral spacers 
The preparation of chiral spacers ligands were described in previous report of our 
group 22. 
H
N
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N
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PPh2
Biot-(R)- and (S)-Phe-1
N
O N
PPh2
PPh2Biot-(R)- and (S)-Pro-1
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In general, the synthesis of enantiopure chiral spacer ligands is achieved by following 
the procedure described below: 
HN
PPh2
PPh2 BocHN CO2H
R
BocHN
N
R
O
PPh2
PPh2
H
N
N
R
O
PPh2
PPh2
H2N
N
R
O
PPh2
PPh2
Biot
O
+
CDMT, rt, 24 h
CH3CN, N-methylmorpholine
TFA, CH2Cl2
anisole, rt, 3 h
Biot-C6F5
EtN(i-Pr)2, DMF, rt, 48 h
 
Scheme 46. Synthesis pathway of biotinylated-diphosphine ligands bearing an enantiopure amino acid 
spacer. 
 
Synthesis of (R)–boc 2-((bis(2-diphenylphosphino)ethyl))carbamoyl) 
piperidine-1-carboxylate (Boc-(R)-Pip-1) 
The diphosphino-amine H–1 HCl (1.0 g, 2.1 mmol), (R)-Boc 2-Piperidine 
Carboxylic Acid (0.49 g, 2.1 mmol) and CDMT (0.38 g, 2.3 mmol) were mixed in 
degassed acetonitrile (95 mL) and N-methylmorpholine (0.56 mL, 5.2 mmol) was 
added slowly (after 5 min). The slurry was stirred overnight at room temperature. The 
solvent was removed in vacuo and the crude precipitate was purified by column 
chromatography on silica gel 60 F254 using Hexane/EtOAc : 8/2 as eluent, allowing 
isolation of pure product as a white foam. (yield: 0.50 g, 0.76 mmol, 68%). 
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1H NMR (200.00 MHz, CDCl3, 20°C): δ [ppm] = 1.4 (s, 9H; CH3-Boc), 1.5 (m, 6H; 
H9, H8, H7), 1.6 (m, 4H; H1, H4), 3.3 (m, 4H; H2, H3), 3.5 (m, 2H; H10), 4.6 (m, 1H; 
H6), 7.3-7.4 (m, 20H; PhH). 
 
31P NMR (161.98 MHz, CDCl3, 20°C): δ [ppm] = -19.3. 
 
 
Synthesis of (S)–boc 2-((bis(2-diphenylphosphino)ethyl))carbamoyl)piperidine-1-
carboxylate (Boc-(S)-Pip-1) 
The diphosphino-amine H–1 HCl (3.0 g, 6.3 mmol), (S)-Boc 2-Piperidine 
Carboxylic Acid (1.44 g, 6.3 mmol) and CDMT (1.22 g, 6.4 mmol) were charged into 
a 500 mL bottom flask containing degassed acetonitrile (280 mL) and after 5 min, a 
solution of N-methylmorpholine (1.7 mL, 15 mmol) was added slowly. The resulting 
slurry was stirred overnight at room temperature. The solvent was removed in vacuo 
and the crude precipitate was purified by column chromatography on silica gel 60 
F254 using Hexane/EtOAc : 8/2 as eluent, allowing isolation of pure product as a 
white foam. (yield: 0.60 g, 0.92 mmol, 15%). 
 
Synthesis of (R)–benzyl 5-(bis(2-diphenylphosphino)ethyl)amino)-4-(Boc)-5-
oxopentanoate (Boc-(R)-Glu5-Bz-1) 
The diphosphino-amine H–1 HCl (0.5 g, 1.1 mmol), (R)-Boc Glutamic Acid 
Benzyl Ester (0.35 g, 1.1 mmol) and CDMT (0.18 g, 1.1 mmol) were charged into a 
100 mL bottom flask containing degassed acetonitrile (45 mL) and after 5 min, a 
solution of N-methylmorpholine (0.28 mL, 2.5 mmol) was added slowly. The 
resulting slurry was stirred overnight at room temperature. The solvent was removed 
in vacuo and the crude precipitate was purified by column chromatography on silica 
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gel 60 F254 using Hexane/AcOEt : 8/2 as eluent, allowing isolation of pure product as 
a white foam. (yield: 0.68 g, 0.89 mmol, 85%). 
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1H NMR (400.00 MHz, CDCl3, 20°C): δ [ppm] = 1.4 (s, 9H; CH3 Boc), 1.9 (qd, 2H; 
H7), 2.3 (m, 6H; H8, H1, H4), 3.3 (m, 2H; H3), 3.6 (m, 2H; H2), 4.5 (td, 1H; J = 5.2, 
3.8 Hz; H6), 5.1 (dd, 2H; J = 12.2, 9.4 Hz; H10),  5.3 (d, 1H, J = 8.6 Hz; NH), 7.3-7.5 
(m, 25H; PhH, H12, H13, H14, H15, H16). 
 
13C NMR (50 MHz, CDCl3, 20°C): δ [ppm] = 26.6 (CH2), 26.7 (CH2), 28.5 (CH2), 
28.7 (CH3 Boc), 30.2 (CH2), 44.4 (CH2), 45.7 (CH2), 50.1 (CH-O), 66.8 (CH-O), 80.0 
(C Boc), 128.7-133.4 (Ph–H), 136.3-137.8 (Ph–C), 155.8 (CO Boc), 171.9 (CO-N), 
173.0 (CO-O).  
 
31P NMR (161.62 MHz, CDCl3, 20°C): δ [ppm] = -19.7, -20.4. 
 
 
Synthesis of (S)–benzyl 5-(bis(2-diphenylphosphino)ethyl)amino)-4-(Boc)-5-
oxopentanoate (Boc-(S)-Glu5-Bz-1) 
The diphosphino-amine H–1 HCl (0.5 g, 1.1 mmol), (S)-Boc Glutamic Acid 
Benzyl Ester (0.35 g, 1.1 mmol) and CDMT (0.18 g, 1.1 mmol) were added into a 45 
mL degassed acetonitrile. After stirring for ca. 5 min, a solution of N-
methylmorpholine (0.28 mL, 2.5 mmol) was added slowly to the mixture. The slurry 
was then stirred overnight at room temperature. The solvent was removed in vacuo 
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and the crude precipitate was purified by column chromatography on silica gel 60 
F254 using Hexane/AcOEt : 8/2 as eluent, allowing isolation of pure product as a 
white foam. (yield: 0.61 g, 0.80 mmol, 76%). 
 
General procedure of deprotection of  N-boc amino acid diphosphine 
 
The Boc group was removed by addition of 20 equiv TFA in dichloromethane 
(TFA/DCM: 0.5) and 2 equiv of anisole to the protected N-boc. All solvent was 
degassed before use for ca. 15 min. Upon stirring the reaction mixture (rt, 3 h 
approximately), the solvent was evaporated in vacuo to dryness. The resulting 
precipitate was used for coupling with biotin without further purification. 
 
Synthesis of Biot-(R)-Pip-1 
A solution of BiotOC6F5 (0.38 mg, 0.9 mmol) in DMF (45 mL) was added at 
room temperature to the deprotected aminodiphosphine H-(R)-Pip (0.5 g, 0.9 mmol). 
The reaction mixture was then stirred under N2. A solution of N-N-
Diisopropylethylamine (0.6 mL, 3.7 mmol) was added to the slurry. After 48 h of 
mixing, the solvent of resulting mixture was dried under vacuum. The product (white 
foam) was then purified by silica gel CHCl3/MeOH = 12:1 (yield: 0.19 g, 0.24 mmol, 
22%). 
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1H NMR (400.00 MHz, CDCl3, 20°C): δ [ppm] = 1.8-1.3 (m, 16H; Hα, Hβ, Hχ, H1, 
H4, H7, H8, H9), 2.3 (m, 2H; Hδχ), 2.7 (dd, 1H,  J = 12.8 Hz, J = 4.8 Hz; H1’b), 2.8 
(dd, 1H,  J = 12.8 Hz, J = 4.8 Hz; H1’a), 3.1 (m, 1H; H7’), 3.3 (m, 2H; H10), 3.7 (m, 
4H; H2, H3), 4.2 (m, 1H; H6’), 4.3 (m, 1H; H2’),  4.4 (dd, 1H, J = 7.7 Hz, J = 4.6 Hz; 
H6), 6.5-5.7 (s, 1H; H3’, H5’), 7.3-7.5 (m, 20H; PhH). 
 
13C NMR (50 MHz, CDCl3, 20°C): δ [ppm] = 25.0-33.6 (CH2; C1, C4, C7, C8, C9, Cα, 
Cβ, Cχ, Cδ), 40.8 (CH2-S), 45.6 (CH2), 43.9 (CH2; C2, C3), 50.1 (CH-N), 55.9 (CH-S), 
60.7 (C2’), 62.3 (C6’), 128.9-133.5 (Ph–H), 136.3-140.1 (Ph–C), 164.3 (N-CO-N), 
172.7 (CO), 174.7 (Cε).  
 
31P NMR (161.62 MHz, CDCl3, 20°C): δ [ppm] = -19.9, -20.2. 
 
ESI MS C44H52N4O3P2S (778.32): 779.3 (100%) [M+H]+. 
 
Synthesis of Biot-(S)-Pip-1 
A solution of BiotOC6F5 (0.4 mg, 1.03 mmol) in DMF (50 mL) was added at 
room temperature to the deprotected aminodiphosphine H-(S)-Pip (0.57 g, 1.03 
mmol). The reaction mixture was then stirred under N2. A solution of N-N-
Diisopropylethylamine (0.7 mL, 5.4 mmol) was then added to the slurry. Upon 
mixing (for ca. 48 h), the solvent of resulting mixture was dried under vacuum. The 
product (white foam) was then purified by silica gel CH2Cl2/MeOH = 12:1 (yield: 
0.36 g, 0.46 mmol, 44%). 
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1H NMR (400.00 MHz, CDCl3, 20°C): δ [ppm] = 1.7-1.4 (m, 16H; Hα, Hβ, Hχ, H1, 
H4, H7, H8, H9), 2.3 (m, 2H; Hδ), 2.7 (m, 1H; H1’b), 2.8 (m, 1H; H1’a), 3.1 (m, 1H; 
H7’), 3.3 (t, 2H, J = 5.3 Hz; H10), 3.7 (m, 4H; H2, H3), 4.2 (dd, 1H, J = 12.8 Hz, J = 
4.5 Hz; H6’), 4.4 (dd, 1H, J = 12.8 Hz, J = 4.5 Hz; H2’),  4.9 (m, 1H; H6), 5.5-6.1 (s, 
1H; H3’, H5’), 7.3-7.4 (m, 20H; PhH). 
 
13C NMR (50 MHz, CDCl3, 20°C): δ [ppm] = 19.2-33.2 (CH2; C1, C4, C7, C8, C9, Cα, 
Cβ, Cχ, Cδ), 40.3 (CH2-S), 43.6 (CH2; C2, C3), 45.6 (CH2; C10), 50.0 (CH-N), 55.4 
(CH-S), 60.4 (C2’), 61.9 (C6’), 128.5-133.0 (Ph–H), 135.5-139.7 (Ph–C), 164.0 (N-
CO-N), 172.1 (CO), 174.2 (Cε).  
 
31P NMR (161.62 MHz, CDCl3, 20°C): δ [ppm] = -20.98, -21.17. 
 
ESI MS C44H52N4O3P2S (778.32): 779.3 (100%) [M+H]+. 
 
 
Synthesis of Biot-(R)-Glu5-Bz-1 
BiotOC6F5 (0.44 mg, 1.06 mmol) was dissolved in DMF (59 mL). The slurry 
was added at room temperature to the deprotected aminodiphosphine H-(R)-Glu5-Bz 
(0.58 g, 1.06 mmol) under N2. A solution of N-N-Diisopropylethylamine (0.6 mL, 3.7 
mL) was added to the slurry. After 48 h of mixing, the solvent of resulting mixture 
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was dried under vacuum. The product (white foam) was then purified by silica gel 
CH2Cl2/EtOH = 30:1 (yield: 0.16 g, 0.18 mmol, 17%). 
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1H NMR (400.00 MHz, CDCl3, 20°C): δ [ppm] = 1.2-1.9 (m, 9H; Hα, Hβ, Hχ, H1, 
H4), 2.2-2.4 (m, 6H; Hδ, H7, H8), 2.8 (dd, 2H,  J = 8.00 Hz, J = 4.8 Hz; H1’), 3.2 (m, 
1H; H7’), 3.5 (m, 4H; H2, H3), 4.2 (dd, 1H,  J = 3.4 Hz, J = 4.4 Hz; H6’), 4.3 (dd, 1H;  
J = 4.8 Hz, J = 4.4 Hz; H2’),  4.7 (m, 1H; H6), 5.0 (m, 2H; H10),  6.7 (s, 2H; H3’, H5’), 
7.3-7.5 (m, 25H; PhH, H12, H13, H14, H15, H16) 8.0 (s, 1H; NH). 
 
13C NMR (50 MHz, CDCl3, 20°C): δ [ppm] = 25.9-35.9 (CH2; C1, C4, C7, C8, C9, Cα, 
Cβ, Cχ, Cδ), 40.9 (CH2-S), 44.4 (CH2; C2, C3), 48.7 (CH-N), 55.9 (CH-S), 60.8 (C2’), 
61.9 (C6’), 66.8 (CH2-O), 128.7-133.6 (Ph–H), 136.3-138.3 (Ph–C), 165,2 (N-CO-N), 
172.8 (CO-N).  
 
31P NMR (161.62 MHz, CDCl3, 20°C): δ [ppm] = -20.22, -20.3. 
 
ESI MS C50H56N4O5P2S (886.34): 887.3 (100%) [M+H]+. 
 
 
Synthesis of Biot-(S)-Glu5-Bz-1 
BiotOC6F5 (0.33 mg, 0.79 mmol) was dissolved in DMF (45 mL). The 
mixture was then added at room temperature to the deprotected aminodiphosphine H-
(S)-Glu5-Bz (0.44 g, 0.79 mmol). The reaction mixture was then stirred under N2. A 
solution of N-N-Diisopropylethylamine (0.52 mL, 3.2 mmol) was added at last. Upon 
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stirring (for ca. 48 h), the solvent of resulting mixture was dried under vacuum. The 
product (white foam) was then purified by silica gel using 100 mL CHCl3, 150 mL 
CHCl3/MeOH = 30:1, and 200 mL CHCl3/MeOH = 15:1 (yield: 0.25 g, 0.28 mmol, 
35%). 
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1H NMR (400.00 MHz, CDCl3, 20°C): δ [ppm] = 1.3-1.8 (m, 9H; Hα, Hβ, Hχ, H1, 
H4), 2.2-2.4 (m, 6H; Hδ, H7, H8), 2.8 (dd, 2H,  J = 7.9 Hz, J = 4.8 Hz, H1’), 3.2 (m, 
1H, H7’), 3.4 (m, 4H; H2, H3), 4.2 (dd, 1H,  J = 3.2 Hz, J = 4.6 Hz, H6’), 4.4 (dd, 1H;  
J = 4.8 Hz, J = 3.6 Hz, H2’),  4.7 (dd, J = 4.7 Hz, J = 8.4 Hz, 1H; H6), 5.1 (m, 2H; 
H10),  7.1 (s, 2H; H3’, H5’), 7.3-7.5 (m, 25H; PhH, H12, H13, H14, H15, H16). 
 
13C NMR (50 MHz, CDCl3, 20°C): δ [ppm] = 25.8-36.2 (CH2; C1, C4, C7, C8, C9, Cα, 
Cβ, Cχ, Cδ), 40.8 (CH2-S), 44.5 (CH2; C2, C3), 48.8 (CH-N), 56.2 (CH-S), 60.7 (C2’), 
62.44 (C6’), 66.7 (CH2-O), 128.7-133.6 (Ph–H), 136.3-138.3 (Ph–C), 165,1 (N-CO-
N), 172.9 (CO-N).  
 
31P NMR (161.62 MHz, CDCl3, 20°C): δ [ppm] = -20.36, -20.41. 
 
ESI MS C50H56N4O5P2S (886.34): 887.3 (100%) [M+H]+. 
 
5.3. Production and purification of streptavidin  
The expression of mutant proteins Sav S112X has been described in the 
previous reports 21, 164. Whereas, WT Avi was purchased from Belovo. 
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5.4. Enantioselective hydrogenation reactions 
5.4.1. General Aspects 
All aqueous and organic solvents were flushed with nitrogen during at least 
three hours. All manipulations were performed in a nitrogen atmosphere glove box. 
The metal source [Rh(COD)2]BF4 was dissolved in DMSO  (4 mg, 16 mL DMSO), 
1.56 mmol of this solution was added to the appropriate aliquoted ligand (2.02 mmol, 
1.3 equiv with respect to the metal source). This solution was stirred for ca. 10 min. 
5.4.2. Hydrogenation in Monophasic media (9%, 27%, 45% DMSO)  
A Pyrex tube (volume ca. 3 mL) was placed in an autoclave and charged with 
an N-acetamidoacrylic acid solution in MES buffer 0.38 M (130 µL of a 23.85 mM 
solution, 3.10 µmol), and an N-acetamidocinnamic acid solution in MES buffer 
0.38M (130 µL of a 23.85 mM solution, 3.10 µmol). The volume was adjusted with 
water (or with DMSO, depending on the ratio of DMSO to be used) to 900 µL. The 
protein solution in water was then added (100 µL of a 0.207 mM solution, 0.0207 
µmol of the tetramer). The precatalyst solution in DMSO (100 µL, 0.062 µmol) was 
added last. The resulting mixture was vortexed, removed from the glove box and 
hydrogenated at 5 bars H2 for 15 h.  
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5.4.3. Hydrogenation in Biphasic Media (EtOAc)  
A Pyrex tube (volume ca. 3 mL) was placed in an autoclave and charged with 
an N-acetamidoacrylic acid solution in EtOAc (550 µL of a 5.66 mM solution, 3.10 
µmol), and an N-acetamidocinnamic acid solution in EtOAc (550 µL of a 5.66 mM 
solution, 3.10 µmol). The buffer solution (580 µL of a 0.38 M solution) was added 
and the volume of the aqueous phase was adjusted with water to 900 µL. The protein 
solution in water was then added (100 µL of a 0.207 mM solution, 0.0207 µmol of the 
tetramer). The precatalyst solution in DMSO (100 µL, 0.062 µmol) was added last. 
The resulting mixture was vortexed and hydrogenated at 5 bars H2 for 15 h using 
orbital shaking (ca. 200 rpm). 
Note: In the case of hydrogenation without protein, the volume of the protein solution 
was replaced by H2O. 
All experiments were performed using MES buffer only. This change does not 
influence significantly the activity and enantioselectivity of experiments using avidin 
as the host protein. 
5.4.4. Hydrogenation procedure for Immobilized Artificial Metalloenzymes  
The commercial suspension of D-biotin-sepharose CL-4B (105 mL, which 
corresponds to 0.031 mmol biotin, capable of immobilizing 0.031 mmol tetrameric 
(strept)avidin) (Affiland, Belgium, suspension in TBS buffer pH 7.4, NaN3 0.02% 
(w/v)) was decanted and washed with water to afford wet beads, which were 
resuspended in water (105 mL total volume). The protein solution (0.062 mmol,  2 
equiv vs. biotin sepharose, 300 mL) was added. After ca. 10 min incubation, the 
immobilized protein (containing 0.031 mmol of protein, corresponding to 0.093 
mmol, free active sites) was washed at least three times with H2O to remove the 
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unbound protein and flushed with nitrogen for three hours. The precatalyst solution in 
DMSO (100 µL, 0.062 µmol, 0.66 equiv with respect to the free biotin-binding sites) 
was added last and was incubated with the immobilized protein for 10 min. The 
immobilized catalyst was subjected to several cycles of washing and decanting. The 
catalytic runs were performed according to the standard orbital shaking procedure. 
5.4.5. Hydrogenation procedure for the determination of Michaelis-Menten 
parameters  
A 15-mL glass vessel was charged with a quantity (depending on the number 
of equivalent of substrates used) α-acetamidoacrylic acid in MES buffer (0.1 M, pH = 
5.5). The volume was adjusted with water to 9 mL followed by addition of 
(strept)avidin in H2O (1 mL, 0.207 mM solution, 0.207 mmol of tetramer). The 
catalyst precursor [Rh(COD)(spacer)]+ in DMSO (1 mL, 0.62 mmol) was added last. 
The resulting mixture was stirred for ca. 2 min to ensure a homogeneous medium. 
The reactor was closed and was removed from the glove box and pressurized to 2 bars 
H2 and stirred mechanically at room temperature. Aliquots (ca. 0.5 mL) were sampled 
at given times. 
The initial conversions were collected for each concentration of substrate. The initial 
rate of the reaction (ν) can be calculated by: 
ν = ([substrate]0·conversion)/t  
This value gives observed initial rate. The calculated initial rate can be obtained by 
employing the following equation: 
! 
" =
V
max
S[ ]
K
M
+ S[ ]
 
with: 
! 
V
max
= k
cat
E[ ]
0
 
ν  = initial rate of reaction 
Vmax = maximum rate of reaction (kinetic saturation) 
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[S] = concentration of substrate 
[E]0 = initial concentration of enzyme (catalyst) 
KM = Michaelis-Menten (dissociation of substrate-catalyst complex) constant 
kcat = rate constant (turnover number) of reaction 
The initial guessed values of both unknowns (KM and Vmax) were introduced in the 
calculation. Thereafter, a least squares-minimization was performed to obtain the 
calculated initial rate ν of the reaction and the Michaelis-Menten parameters. 
5.4.6. Kinetics experiments using Michaelis-Menten models 
Conversions of the reaction were collected from the independent experimental 
by varying the concentration of the substrate. The observed initial rate can thus be 
calculated by dividing the initial conversion with time. The calculated initial rate can 
be computed by introducing the initial guess values of Michaelis parameters (kcat and 
KM). To minimize the error between observed and calculated initial rate, a least-
squares minimization was performed resulting kcat and KM. The ensemble data are 
collected and summarized in Table 16-21. 
Table 16. Kinetic experiments data of [Rh(COD)(Biot-1)]+ ⊂ WT Sav 
C[a] substrate 
[mM] 
time (min) conv. (%) 
νinitial 
(mM·min-1) 
νinitial calc[b] 
(mM·min-1) 
0.00 0 0 0.00 0.00 
2.83 2 8 0.11 0.12 
3.96 3 11 0.15 0.14 
5.09 3 9 0.15 0.16 
5.65 5 15 0.17 0.16 
11.30 5 9 0.20 0.20 
16.95 10 12 0.20 0.21 
28.25 10 8 0.23 0.23 
33.90 10 7 0.24 0.23 
[a]C = concentration; [b]calc = calculated 
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Table 17. Kinetic experiments data of [Rh(COD)(Biot-1)]+ 
C[a] substrate 
[mM] time (min) conv. (%) 
νinitial 
(mM·min-1) 
νinitial calc[b] 
(mM·min-1) 
0.00 0 0 0.00 0.00 
2.83 5 8 0.05 0.05 
5.09 6 8 0.07 0.07 
5.65 10 13 0.07 0.07 
11.30 10 10 0.11 0.10 
16.95 10 7 0.12 0.12 
28.25 10 5 0.14 0.14 
33.90 15 6 0.14 0.14 
[a]C = concentration; [b]calc = calculated 
 
Table 18. Kinetic experiments data of [Rh(COD)(Biot-(R)-Pro-1)]+ ⊂ WT Sav in the presence of 30% 
DMSO 
C[a] substrate 
[mM] time (min) conv. (%) 
νinitial 
(mM·min-1) 
νinitial calc[b] 
(mM·min-1) 
0.00 0 0 0.00 0.00 
2.83 3 22 0.21 0.23 
5.09 5 31 0.32 0.33 
5.65 5 33 0.37 0.34 
11.30 5 20 0.45 0.45 
16.95 5 15 0.51 0.49 
28.25 10 19 0.54 0.54 
33.90 15 24 0.54 0.56 
[a]C = concentration; [b]calc = calculated 
Table 19. Kinetic experiments data of [Rh(COD)(Biot-(R)-Pro-1)]+ ⊂ WT Sav in the presence of 30% 
DMSO 
C[a] substrate 
[mM] time (min) conv. (%) 
νinitial 
(mM·min-1) 
νinitial calc[b] 
(mM·min-1) 
0.00 0 0 0.00 0.00 
2.83 3 23 0.22 0.27 
5.09 5 38 0.39 0.37 
5.65 5 37 0.42 0.39 
11.30 5 23 0.52 0.50 
16.95 5 17 0.58 0.55 
28.25 10 21 0.59 0.60 
33.90 15 26 0.59 0.62 
[a]C = concentration; [b]calc = calculated 
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Table 20. Kinetic experiments data of [Rh(COD)(Biot-(R)-Pro-1)]+ 
C[a] substrate 
[mM] time (min) conv. (%) 
νinitial 
(mM·min-1) 
νinitial calc[b] 
(mM·min-1) 
0 0 0 0 0 
2.83 5 6 0.034 0.038 
5.09 6 6 0.051 0.057 
5.65 10 12 0.068 0.060 
11.3 10 8 0.090 0.084 
16.95 15 8 0.090 0.097 
28.25 15 6 0.113 0.110 
33.9 15 5 0.113 0.114 
[a]C = concentration; [b]calc = calculated 
Table 21. Kinetic experiments data of [Rh(COD)(Biot-(R)-Pro-1)]+ in the presence of 30% DMSO 
C[a] substrate 
[mM] time (min) conv. (%) 
νinitial 
(mM·min-1) 
νinitial calc[b] 
(mM·min-1) 
0 0 0 0 0 
2.83 3 5 0.047 0.053 
5.09 5 7 0.071 0.077 
5.65 5 8 0.090 0.082 
11.3 5 5 0.113 0.112 
16.95 5 4 0.136 0.128 
28.25 10 5 0.141 0.145 
33.9 15 6.5 0.147 0.149 
[a]C = concentration; [b]calc = calculated 
 
As comparison to linearization methods, we describe hereafter the 
linearization data treatment using Lineweaver-Burk plot 174. The kinetics parameters 
then can be compiled by modifying the Michaelis-Menten equations. 
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Figure 16. Lineweaver-Burk plot for each of the following system: [Rh(COD)(Biot-1)]+ ⊂ WT Sav 
(a); [Rh(COD)(Biot-1)]+ (b); [Rh(COD)(Biot-(R)-Pro-1)]+ ⊂ WT Avi  30 % DMSO (c); 
[Rh(COD)(Biot-(R)-Pro-1)]+ ⊂ WT Sav 30 % DMSO (d); [Rh(COD)(Biot-1)]+ (e); [Rh(COD)( Biot-
(R)-Pro-1)]+ 30 % DMSO (f). Model equation is highlighted in red line in comparison with the 
observed data with calculated parameters (Vmax, KM, and R2). 
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5.4.7. Analytical data for reduction products 
Permabond-L-Chirasyl-Val (Macheray-Nagel), 25 m x 0.25 mm column: He carrier 
gas: 1.2 bar, inlet injector 280°C, oven (85°C; 10 min, 8°C/min; 135°C; 0 min, 
10°C/min; 180°C; 35min), FID detector 200 °C; retention time:  
Methyl N-acetylacetamidoacrylate: 9.3 min, 
Methyl (R)-N-acetylacetamidoalanine: 17.2 min,  
Methyl (S)-N-acetylacetamidoalanine: 18.5 min,  
Methyl (R)-N-acetylacetamidophenylalanine: 35.4 min,  
Methyl (S)-N-acetylacetamidophenylalanine: 36.1 min,  
Methyl N-acetylacetamidocinnamate: 53.2 min. 
 
Lipodex E, 25 m x 0.25 mm column: He carrier gas: 0.6 bar, inlet injector 280°C, 
oven (120°C; 10 min, 8°C/min; 10°C/min; 180°C; 10 min), FID detector 250 °C; 
retention time:  
ketopantolactone: 23.7 min, 
(R)-(-)-pantolactone: 25.0 min,  
(S)-(-)-pantolactone: 25.3 min. 
5.5. Titration Procedure 
 The activity of the host protein was determined using Gruber’s protocol based 
on the fluorescence quenching of biotinylated fluorescein upon incorporation in 
(strept)avidin 49, 159.  
 All solutions were prepared and measured at room temperature in a phosphate 
buffer (pH = 7.0, I = 0.15 M). All aliquots were added using micropipettes. The 
collected data were analyzed and fitted using the programs SPECFIT/32 160-162.  
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 Aliquots of a Λ- or Δ-[Ru(bpy)2(Biot-bpy)]2+ solution (0.96 mM for Λ-
[Ru(bpy)2(Biot-bpy)]2+  and 0.64  mM for Δ-[Ru(bpy)2(Biot-bpy)]2+) were added to 
(strept)avidin (8 µM initial concentration, 2400 µL, 19.2 nmol) in 0.25 equiv steps (5 
µL per step, up to 6 equiv) relative to the tetrameric protein. The CD measurements 
(250-500 nm, band width 2 nm, step resolution 0.5 nm, response time 4 s, 3 
accumulations) were recorded at 50 nm/min after thorough vortex mixing (1 min at 
rt). 
5.6. Data treatment using SPECFIT/32 
5.6.1. Spectra of each species  
 Spectra of each absorbing species obtained from SPECFIT/32 are depicted in 
Figure 17 and Figure 18. As can be appreciated, the observed spectra of biotinylated 
complexes and apo-protein fit very well with the calculated spectra.  
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Figure 17. Refined CD spectra for each absorbing species for (Λ-1)x ⊂ streptavidin, x = 0: red line, x = 
2: green line, x = 3: brown line and x = 4: violet line. For comparison, the measured spectra for the host 
protein and for the biotinylated guest Λ-1 are displayed as open circles and full triangles respectively, 
overlaid with the corresponding refined spectra (thin lines). 
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Figure 18. Refined CD spectra for each absorbing species for (Δ-1)x ⊂ avidin, x = 0: red line, x = 2: 
green line, x = 3: brown line and x = 4: violet line. For comparison, the measured spectra for the host 
protein and for the biotinylated guest Δ-1 are displayed as open circles and full triangles respectively, 
overlaid with the corresponding refined spectra (thin lines). 
 
5.6.2. Simulations for the Δ-1 ⊂  streptavidin system using SPECFIT/32 
Simulated data sets were generated with SPECFIT/32 using a constant noise 
level and the following conditions:  
[streptavidin]0 = 7 × 10–6 M 
[Δ-1]0 = 9.6 × 10–4 M 
Initial volume of streptavidin solution: V0 = 2400 µL.  
The solution of ruthenium complex Δ-[Ru(bpy)2(Biot-bpy)]2+ Δ-1 is added in 0.005 
mL increments up to 26 aliquots.  
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Equilibrium constants derived from Table 3 (Chapter 2) were rounded off. Values 
were as follows: 
streptavidin   +      Δ-1       (Δ-1) ⊂ streptavidin log β1 = 8 (1) 
streptavidin   +   2 Δ-1       (Δ-1)2 ⊂ streptavidin log β2 = 19 (2) 
streptavidin   +   3 Δ-1       (Δ-1)3 ⊂ streptavidin log β4 = 28 (3) 
streptavidin   +   4 Δ-1       (Δ-1)4 ⊂ streptavidin log β4 = 36 (4) 
 
Figure 19 shows a distribution diagram of the various species formed under these 
conditions during the simulated experiment. 
 
Figure 19. Species distribution diagram calculated for the above mentioned conditions (For each 
absorbing species for (Δ-[Ru(bpy)2(Biot-bpy)]2+)x ⊂ streptavidin ((Δ-[Ru(bpy)2(Biot-bpy)]2+)x ⊂ 
streptavidin). x = 0: black solid line, x = 1:red line, x = 2: blue line, x = 3: green line  and x = 4: black 
dotted line.The fraction of the (Δ-[Ru(bpy)2(Biot-bpy)]2+) ⊂ streptavidin  species does not exceed 1.4 
%. 
 
The individual CD spectra corresponding to each species used to construct the 
artificial data are displayed in Figure 20. The CD molar absorption Δε for (Δ-
[Ru(bpy)2(Biot-bpy)]2+) ⊂ streptavidin were deduced from the experimentally refined 
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spectra obtained for (Δ-[Ru(bpy)2(Biot-bpy)]2+)2 ⊂ streptavidin by dividing the 
corresponding CD molar absorption Δε values by a factor of 2.  
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Figure 20. Fixed CD spectra used to generate the artificial data sets. For each absorbing species for (Δ-
[Ru(bpy)2(Biot-bpy)]2+)x ⊂ streptavidin ((Δ-[Ru(bpy)2(Biot-bpy)]2+)x ⊂ streptavidin).  x = 0: violet line, 
x = 1: green line, x = 2: red line, x = 3: blue line and x = 4: black solid line. The spectrum of Δ-
[Ru(bpy)2(Biot-bpy)]2+ is displayed as a dotted black line. 
 
5.7. Experimental data of enantioselective hydrogenation 
Table 22. Numerical results of enantioselective hydrogenation 
        
ee[a] Conv. ee[a] Conv.  
Entry Ligand Protein 
N-AcPhe N-AcPhe N-AcAla N-AcAla  
1 Biot–(R)-Pro–1 WT Avi -89 quant.
 [b] -87 quant. [b]  
2 Biot–(S)-Pro–1 WT Avi 20 75 12 quant.
 [b]  
3 Biot–(R)-Phe–1 WT Avi -10 60 -5 quant.
 [b]  
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4 Biot–(S)-Phe–1 WT Avi -12 98 -12 
quant. [b] 
 
5 Biot–(R)-Pro–1 WT Sav -91 quant.
 [b] -87 
quant. [b] 
 
6 Biot–(S)-Pro–1 WT Sav 23 
quant. [b] 
21 
quant. [b] 
 
7 Biot–(R)-Phe–1 WT Sav 63 
quant. [b] 
65 
quant. [b] 
 
8 Biot–(S)-Phe–1 WT Sav -64 87 -73 
quant. [b] 
 
9 Biot–(R)-Pro–1 S112A -82 85 -69 
quant. [b] 
 
10 Biot–(S)-Pro–1 S112A 6 70 22 
quant. [b] 
 
11 Biot–(R)-Phe–1 S112A 44 51 61 
quant. [b] 
 
12 Biot–(S)-Phe–1 S112A -50 85 -65 
quant. [b] 
 
13 Biot–(R)-Pro–1 S112C -88 46 -88 
quant. [b] 
* 
14 Biot–(S)-Pro–1 S112C 0 86 21 
quant. [b] 
 
15 Biot–(R)-Phe–1 S112C 36 67 62 
quant. [b] 
 
16 Biot–(S)-Phe–1 S112C -3 98 -16 
quant. [b] 
 
17 Biot–(R)-Pro–1 S112D -81 72 -85 
quant. [b] 
 
18 Biot–(S)-Pro–1 S112D 0 31 9 
quant. [b] 
 
19 Biot–(R)-Phe–1 S112D 53 48 61 
quant. [b] 
 
20 Biot–(S)-Phe–1 S112D -68 90 -85 
quant. [b] 
 
21 Biot–(R)-Pro–1 S112E -55 16 -79 
quant. [b] 
 
22 Biot–(S)-Pro–1 S112E -11 16 1 91  
23 Biot–(R)-Phe–1 S112E 70 88 76 
quant. [b] 
 
24 Biot–(S)-Phe–1 S112E -70 85 -84 
quant. [b] 
 
25 Biot–(R)-Pro–1 S112F -93 91 -84 
quant. [b] 
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26 Biot–(S)-Pro–1 S112F 24 37 44 
quant. [b] 
* 
27 Biot–(R)-Phe–1 S112F 41 48 62 quant.
 [b]  
28 Biot–(S)-Phe–1 S112F 63 75 63 
quant. [b] 
 
29 Biot–(R)-Pro–1 S112G -47 18 -56 
quant. [b] 
 
30 Biot–(S)-Pro–1 S112G 37 95 54 
quant. [b] 
 
31 Biot–(R)-Phe–1 S112G 13 88 53 
quant. [b] 
 
32 Biot–(S)-Phe–1 S112G -48 quant.
 [b] 0 
quant. [b] 
 
33 Biot–(R)-Pro–1 S112H -77 93 -78 
quant. [b] 
 
34 Biot–(S)-Pro–1 S112H -26 8 25 
quant. [b] 
 
35 Biot–(R)-Phe–1 S112H 69 33 78 
quant. [b] 
 
36 Biot–(S)-Phe–1 S112H -78 65 -87 
quant. [b] 
* 
37 Biot–(R)-Pro–1 S112I -57 52 -57 
quant. [b] 
 
38 Biot–(S)-Pro–1 S112I 1 69 17 
quant. [b] 
 
39 Biot–(R)-Phe–1 S112I 74 80 84 
quant. [b] 
* 
40 Biot–(S)-Phe–1 S112I 50 99 27 
quant. [b] 
* 
41 Biot–(R)-Pro–1 S112K -84 36 -88 quant.
 [b] * 
42 Biot–(S)-Pro–1 S112K -35 12 0 86  
43 Biot–(R)-Phe–1 S112K 67 64 79 
quant. [b] 
 
44 Biot–(S)-Phe–1 S112K -48 62 -59 
quant. [b] 
 
45 Biot–(R)-Pro–1 S112L -55 13 -20 81  
46 Biot–(S)-Pro–1 S112L -15 99 7 
quant. [b] 
 
47 Biot–(R)-Phe–1 S112L 74 88 83 
quant. [b] 
* 
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48 Biot–(S)-Phe–1 S112L 66 quant.
 [b] 36 
quant. [b] 
 
49 Biot–(R)-Pro–1 S112M -82 63 -85 
quant. [b] 
 
50 Biot–(S)-Pro–1 S112M 3 61 26 
quant. [b] 
 
51 Biot–(R)-Phe–1 S112M 75 94 86 
quant. [b] 
* 
52 Biot–(S)-Phe–1 S112M 87 quant.
 [b] 73 
quant. [b] 
* 
53 Biot–(R)-Pro–1 S112N -86 88 -89 
quant. [b] 
 
54 Biot–(S)-Pro–1 S112N 6 16 15 
quant. [b] 
 
55 Biot–(R)-Phe–1 S112N 62 38 70 
quant. [b] 
 
56 Biot–(S)-Phe–1 S112N -68 73 -88 quant.
 [b] * 
57 Biot–(R)-Pro–1 S112P -79 18 -85 92  
58 Biot–(S)-Pro–1 S112P 54 20 62 
quant. [b] 
 
59 Biot–(R)-Phe–1 S112P 61 23 72 
quant. [b] 
 
60 Biot–(S)-Phe–1 S112P -34 24 -50 
quant. [b] 
 
61 Biot–(R)-Pro–1 S112Q -87 52 -88 
quant. [b] 
* 
62 Biot–(S)-Pro–1 S112Q 11 74 9 
quant. [b] 
 
63 Biot–(R)-Phe–1 S112Q 76 82 81 
quant. [b] 
* 
64 Biot–(S)-Phe–1 S112Q -31 98 -54 
quant. [b] 
 
65 Biot–(R)-Pro–1 S112R -88 54 -92 
quant. [b] 
 
66 Biot–(S)-Pro–1 S112R -31 73 -12 
quant. [b] 
 
67 Biot–(R)-Phe–1 S112R 82 75 84 
quant. [b] 
* 
68 Biot–(S)-Phe–1 S112R -33 66 -31 
quant. [b] 
 
69 Biot–(R)-Pro–1 S112T -68 88 -68 
quant. [b] 
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70 Biot–(S)-Pro–1 S112T -2 95 17 
quant. [b] 
 
71 Biot–(R)-Phe–1 S112T 49 94 67 
quant. [b] 
 
72 Biot–(S)-Phe–1 S112T -62 quant.
 [b] -61 
quant. [b] 
 
73 Biot–(R)-Pro–1 S112V -56 74 -77 
quant. [b] 
 
74 Biot–(S)-Pro–1 S112V -42 53 -2 
quant. [b] 
 
75 Biot–(R)-Phe–1 S112V 28 44 59 
quant. [b] 
 
76 Biot–(S)-Phe–1 S112V -66 92 -54 
quant. [b] 
 
77 Biot–(R)-Pro–1 S112W -95 quant.
 [b] -95 
quant. [b] 
* 
78 Biot–(S)-Pro–1 S112W -2 20 5 
quant. [b] 
 
79 Biot–(R)-Phe–1 S112W 66 56 74 
quant. [b] 
 
80 Biot–(S)-Phe–1 S112W 27 51 38 
quant. [b] 
* 
81 Biot–(R)-Pro–1 S112Y -93 97 -92 
quant. [b] 
* 
82 Biot–(S)-Pro–1 S112Y 35 74 27 
quant. [b] 
 
83 Biot–(R)-Phe–1 S112Y 63 61 76 
quant. [b] 
 
84 Biot–(S)-Phe–1 S112Y 73 90 67 
quant. [b] 
* 
        
[a]ee in %, positive ee values in favor of the (R)-enantiomer, negative ee values in favor of the (S)-
enantiomer; [b]quantitative; *selected results for Table 6 in Chapter 3; N-AcPhe = N-
acetamidophenylalanine, N-AcAla = N-acetamidoalanine. 
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